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Abstract 
 
Cardiovascular diseases (CVDs) are more prevalent in comparison with other diseases and 
are one of the leading causes of death worldwide and although current treatments involving 
meticulous, complicated and expensive procedures had some success, in general, the improvement 
in survival and quality of life is not sufficient. 
Cardiac hypertrophy, described as an increase in the mass and volume of individual 
cardiomyocytes (CMs), is an important determinant for cardiac disease. Although cardiac 
hypertrophy is an adaptive mechanism in specific situations to compensate for an increase in 
workload (for example in patients with hypertension or myocardial infarction), eventually the heart 
becomes incapable of meeting the increased workload imposed upon it, thus resulting in heart 
failure. Since the current animal models for studying heart disease have a low predictability, it is 
imperative to develop new human in vitro model-systems in which the disease phenotype can be 
thoroughly dissected. By combining the robustness of the in vitro human embryonic stem cells 
(hESC) model-system for differentiating towards CM-like cells with cutting edge bioengineering, it is 
proposed to develop a platform and a protocol/procedure that assembly efficiency, accuracy and 
automation, e.g. high-throughput, for analysis of the phenotypic characteristics of CM hypertrophy. 
It implies the attachment of a custom-made protein patterned coverslip to the bottom of a 96-well 
plate, enabling the control of CM shape and orientation, upon their culture. Cardiomyocytes were 
analysed and specific algorithms were created and optimized for measuring several CM features, 
which are altered during hypertrophy, such as area and sarcomere intensity, among others. 
Compounds that are known to be in the genesis of this disease are used in this work to 
experimentally induce hypertrophy in CMs. Compounds that are known to be in the genesis of this 
disease were used in this work to experimentally induce hypertrophy in CMs. 
Results suggested an increase in CM area and sarcomere intensity, when cultured together 
with fetal calf serum (FCS) hypertrophic treatment in a fibronectin substrate, but were inconsistent 
for the remaining treatments. Evidences of a CM maladaptation to this type of substrate were 
observed, preventing accurate results, which lead to the pursuit of an optimal protein combination 
for CM culture, regarding this work.  
 Furthermore, regarding the limited proliferative capacity of CMs and their inability to 
repopulate/regenerate the adult heart after injury, it is critical to chase alternatives to successfully 
circumvent such hurdles. Thus, under the primary aim of improving the knowledge on cardiac 
diseases, it is anticipated that our strategy may be easily adapted to meet several other 
applications. The proposed high-throughput mode, in particular, is expected to improve the number 
and the time in which a set of compounds with potential to rescue the disease may be identified. 
Moreover, it is envisioned that this new device will be an add-on in the current available systems for 
testing cardiac toxicity and for pre-clinical settings. 
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Resumo 
 
 As doenças cardiovasculares (CVDs) são mais prevalentes em comparação com outras 
doenças e são uma das principais causas de morte em todo o mundo e embora os tratamentos atuais 
envolvendo procedimentos meticulosos, complicados e caros tiveram algum sucesso, em geral, a 
melhoria em sobrevivência e qualidade de vida não é suficiente.  
 A hipertrofia cardíaca, descrita como um aumento da massa e volume de cardiomiócitos 
(CMs) individuais, tem uma grande importância para as doenças cardíacas. Embora a hipertrofia 
cardíaca é um mecanismo adaptativo em situações específicas para compensar o aumento da carga 
de trabalho (por exemplo em pacientes com hipertensão ou com enfarte do miocárdio) 
eventualmente o coração torna-se incapaz de atender ao excesso da carga de trabalho que lhe é 
imposta, resultando em insuficiência cardíaca. Uma vez que os atuais modelos de animais que 
permitem o estudo das doenças cardíacas têm uma baixa previsibilidade é imperativo desenvolver 
novos sistemas-modelo humanos in vitro em que o fenótipo da doença pode ser cuidadosamente 
dissecado. Ao combinar a robustez do sistema-modelo de células estaminais embrionárias humanas 
(hESC), in vitro, para diferenciação em células semelhantes a cardiomiócitos com a inovação em 
bioengenharia, é proposto o desenvolvimento de uma plataforma que combine eficiência, precisão e 
automatização, ou seja, de alto rendimento, para análise das características fenotípicas dos CMs em 
hipertrofia. Isto implica o acoplamento de uma lamela feita por medida com padrões de proteínas 
impressos na sua superfície ao fundo de uma placa de 96 poços, permitindo o controlo da forma e 
orientação dos CMs, após sua cultura. Os cardiomiócitos foram analisados e algoritmos específicos 
foram criados e otimizados para a medição de várias características dos CMs, normalmente 
alterados durante hipertrofia, como área e intensidade dos sarcómeros, entre outros. Compostos 
que são conhecidos por estar na génese da doença são usados para induzir experimentalmente os 
cardiomiócitos em hipertrofia. 
 Os resultados sugeriram um aumento da área e da intensidade dos sarcómeros dos CMs, 
quando cultivados juntamente com o tratamento hipertrófico, com soro de fetal bovino (FCS), num 
substrato constituído por fibronectina, mas foram inconsistentes para os tratamentos restantes. 
Foram observadas evidências de uma má adaptação dos CMs a este tipo de substrato, impedindo a 
precisão dos resultados, que levou à procura da combinação de proteínas ideal para a cultura de 
CMs, para este trabalho.  
 Além disso, em relação ao limitado CMs natureza proliferativa e sua incapacidade para 
repovoar/regenerar o coração adulto após a lesão, é fundamental perseguir alternativas para 
contornar esses obstáculos com sucesso. Assim, sob o objetivo principal de melhorar o 
conhecimento sobre as doenças cardíacas, prevê-se que a estratégia possa ser facilmente adaptada 
para atender a diversas outras aplicações. O modo de alto rendimento proposto, em particular, 
espera-se aumentar o número e o tempo em que um conjunto de compostos com potencial para 
salvar a doença possam ser identificados. Além disso, prevê-se que este novo dispositivo seja uma 
melhoria nos atuais sistemas disponíveis para testar a toxicidade cardíaca e em configurações pré-
clínicos. 
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Chapter 1 Introduction 
 
1.1 Cardiovascular diseases 
Cardiovascular diseases (CVDs) are defined as a class of diseases that involves the 
heart and the associated blood vessels, or both. The causes for cardiovascular diseases are 
diverse; however the most common underlying conditions are arthrosclerosis and/or 
hypertension. Both may lead to a wide range of disorders such as coronary artery disease, 
cardiomyopathy, hypertensive heart disease, heart failure, cor pulmonale, cardiac 
dysrhythmias, inflammatory heart disease (endocarditis and myocarditis), valvular heart 
disease, cerebrovascular disease (stroke), peripheral arterial disease, congenital heart 
disease and rheumatic heart disease.  
CVDs are more prevalent all over the world as compared to other diseases, being one 
of the leading causes of fatalities worldwide, accounting for 17.3 million deaths in 2008, from 
a total of 57 million deaths (Alderman, 2007). In the same year, a study was conducted by the 
World Health Organization, regarding the impact of noncommunicable diseases, which mainly 
include CVDs, cancer, respiratory diseases, digestive diseases and diabetes. It was estimated 
that, from a total of 36 million deaths worldwide caused by noncommunicable diseases, CVDS 
were responsible for the largest proportion of deaths under the age of 70 (39%), as 
represented in Figure 1 (Alderman, 2007; World Health Organization, 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - Percentage of global non -communicable disease deaths under the age of 70, by cause of death in 
2008. (Adapted from World Health Organization, 2011)  
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 There is no expectation for these numbers to decrease and actually it has been 
estimated that by 2030, the number of deaths will increase and reach a total of 23.3 million 
people (Mathers and Loncar, 2006; World Health Organization, 2011). It is also projected that 
CVDs will remain the single leading cause of death (Mathers and Loncar, 2006). 
CVD is not only one of the most relevant causes of death but is also one of the 
greatest contributors to the total burden of disease. Disability-adjusted life years (DALYs), 
which quantify the number of years lost due to disease, are a measure of the total impact of 
a disease including its fatal (premature death) and non-fatal (disability) outcomes (Kelly, 
Narula and Fuster, 2012). One DALY represents the loss of the equivalent of one year of full 
health. This concept is applied to the number of years lost due to premature death or by 
living in disability or in poor health, due to disease, being the measurement of gap between 
current health status and ideal health situation designated burden of disease (World Health 
Organization, 2004). Almost one half of the disease burden in low- and middle-income 
countries is caused by non-communicable diseases, where cardiovascular diseases account for 
more than one quarter of the total disease burden (World Health Organization, 2004). 
Ischaemic heart disease and stroke are the largest sources of this burden, as shown in Table I 
from a study carried by the World Health Organization in 2011 (World Health Organization, 
2011).  
 
Table I – 10 leading global causes of DALY.(Adpated from World Health Organization, 2011) 
 
 
 
 
 
 
 
 
 
 
 
Overall, CVD represents one of the most dangerous diseases in the world and a very 
high index of disease burden. In spite of that, it also entails elevated costs related to the 
health system expenditure for the treatment of the disease (including ambulance, diagnostic 
tests, hospital charges, possible surgery, drugs, testing, cardiologist appointment, 
rehabilitation), representing one of the most expensive diseases throughout the world (Kelly, 
Narula and Fuster, 2012). Just in the USA it was estimated that direct and indirect cost was 
approximately of 400 billion American dollars, in 2006 (Graham et al., 2006). In a recent 
study regarding the most expensive diseases, Stroke was listed in fourth place, Heart Attack 
in sixth and Coronary Artery Disease in seventh (Whelan, 2012). The former three are all 
cardiovascular diseases, or a cause of it, such as heart attack which is a progressive state that 
Rank Cause 
DALYs 
(thousands) 
% DALYs 
1 Ischaemic heart disease 165.717 6,0 
2 Lower respiratory infections 146.864 5,4 
3 Stroke 141.348 5,2 
4 Preterm birth complications 107.210 3,9 
5 Diarrhoeal diseases 99.728 3,6 
6 Chronic obstructive pulmonary disease 92.377 3,4 
7 HIV/AIDS 91.907 3,4 
8 Road injury 78.724 2,9 
9 Unipolar depressive disorders 76.500 2,8 
10 Birth asphyxia and birth trauma 74.600 2,7 
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follows from arthrosclerosis condition. Hereupon, this disease is a great concern that affects 
not only the people's health but also the economic status of the family and even the 
economic vitality of the countries, which have to be taken in count (Alderman, 2007). It is an 
increasing problem with no effective prevention or treatment that can restore the person's 
health.  
 Current remedy involve heart transplant, which implies the risk of immune rejection 
and shortage of organ donors. (Chiu et al., 2012) Although this adverse response can be 
prevented by administration of immunosuppressive drugs for the rest of the life, this can lead 
to several unwanted side effects, such as infections. (Bryers, Giachelli and Ratner, 2012) 
Also, mechanical ventricular assistance devices can be used as a treatment, but the 
implantation of foreign materials into the organism can lead to immune rejection, being 
chronic inflammation and device failure a great concern in this matter (Ratner et al., 2012). 
These problems need to be circumvented with appropriate strategies that enhance the heart 
function recovery. As such, the rapid development of stem cell technology has raised hopes 
for new and even revolutionary treatments for cardiac, promoting heart regeneration.  
 
1.2 Cardiomyocyte hypertrophy 
1.2.1 Morphological alterations 
 Cardiac hypertrophy is characterized by an increase in the mass and volume of 
individual CMs, enhanced protein synthesis and heightened organization of the sarcomeres, 
resulting in an increase of heart weight without affecting the number of CMs (Wang, Huang 
and Sah, 1998; Bray, Sheehy and Parker, 2008; Rohini et al., 2010). Although it can have 
physiological origins and a healthy connotation, it is preoccupant when it is caused by 
pathological stimuli, developed when increased external stimuli such as, hemodynamic 
overload and neurohumoral factors are continuously imposed on cardiac myocytes. 
Classically, two different pathological hypertrophic phenotypes can be distinguished: 
concentric and eccentric hypertrophy (Bray, Sheehy and Parker, 2008). The first develops due 
to pressure overload, which is characterized by parallel addition of sarcomeres, resulting in 
an increase in individual CMs width, often related to hypertension and/or aortic stenosis 
(Grossman, Jones and McLaurin, 1975; Frey et al., 2004; Bray, Sheehy and Parker, 2008; Buja 
and Vela, 2008). The second progresses owing to volume overload or prior infarction, and is 
characterized by addition of sarcomeres in series, producing a greater increase of CM length 
as compared to the width (Grossman, Jones and McLaurin, 1975; Frey et al., 2004; Bray, 
Sheehy and Parker, 2008; Buja and Vela, 2008). The normal, healthy, value for the length-to-
width CM ratio is approximately seven (Bray, Sheehy and Parker, 2008). Consequently, during 
concentric or eccentric hypertrophy this ratio decreases and increases, respectively, from the 
normal value (Bray, Sheehy and Parker, 2008). The heart alterations concerning the two 
different hypertrophic phenotypes are represented in Figure 2. 
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Figure 2 - Heart alterations during cardiac hypertrophy both in concentric and eccentric phenotypes. (Adapted 
from Maillet, van Berlo and Molkentin, 2013) 
 
1.2.2 Genetic alterations 
 During the hypertrophic response, CMs are reprogrammed by activation of a distinct 
pattern of gene expression that eventually results in qualitative and quantitative alterations 
on contractile protein content and the induction of an embryonic gene program (Wang, Huang 
and Sah, 1998; Carèw et al., 2007). Nevertheless, the genetic programs responsible for 
cardiac hypertrophy are diverse and complex and its pathways or proteins which are coupled 
to it and to the structural reorganization of the cell are still unknown. Usually, the fetal gene 
expression programs are derived from a trigger that stimulates key intercellular signalling 
pathways, converging on transcription factors and transduced into the nucleus (Lu and Yang, 
2009; Putinski et al., 2013). The CM hypertrophy process is represented in a simplified form in 
Figure 3. Several intracellular signalling molecules, such as protein kinase C (PKC), tyrosine 
kinases, mitogen-activated protein kinase (MAPK) family, the Janus kinase/signal transducers 
and activators of transcription (JAK/STAT) family, have been reported to play important roles 
in the development of CM hypertrophy (Zou, et al. 2001). Other studies underlie, also, the 
importance of extracellular signal regulated kinase signalling in CM hypertrophy, such as 
extracellular signal-regulated kinases (ERKs) (Carèw et al., 2007). They have been found to 
play an essential role in hypertrophic responses on CMs both in vitro and in vitro, although, 
its activation does not always lead to that outcome (Taigen et al., 2000).  
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Figure 3 - Simplified representation of the hypertrophy process in cardiomyocytes. (Carreño et al., 2006) 
 
1.2.3 Hypertrophic compounds 
It is a fact that the hypertrophic agonist isoprotenerol (ISO), a cathecolamine and a 
β1- and β2-adrenoreceptor agonist, induces expression of proto-oncogenes and cardiac 
growth. It was reported that ISO activates ERKs through both Gs and G1-dependent pathways 
and also by Ca2+, inducing cardiac hypertrophy (Zou et al., 2001). Also, the cathecolamine 
and a α1-adrenergic receptor agonist, phenylephrine (PE), induces the activation of the 
mitogen-activated protein kinases, ERK2 (MAPK1), which plays central roles in MAPK cascades 
and leads to a re-expression of fetal type proteins, a hallmark of CM hypertrophy (Taigen et 
al., 2000; Schäfer et al., 2002). MAPK cascades mediate diverse biological functions such as 
cell growth. Angiontensin II (ANG) is a peptide hormone and the predominant effector of the 
Renin-angiotensin system. It stimulates several signalling molecules, which subsequently 
activate their target genes in the nucleus, leading to CM hypertrophy (Sadoshima et al., 1995; 
Takeishi et al., 2001; Lu and Yang 2009). Endothelin-1 (ET-1) is a potent vasoconstriction 
agent and function as a stimulator of the renin-angiotensin system. Its hypertrophic effects 
have been widely studied and it acts on the G-protein coupled receptors, activating then 
phospholipase C which hydrolyses specific compounds. This leads to the activation of 
hypertrophic signals such as Raf-1 and MAPK (Yamazaki et al., 1996). Fetal calf serum (FCS) is 
composed by several proteins, such as bovine serum albumin (BSA) and by several growth 
factors such as angiotensin II and ET-1 and, therefore, induces a hypertrophic response by a 
non-selective adrenoreceptor stimulation, because of its varied composition (Dubey et al., 
1997; Schäfer et al., 2002). 
 It is generally assumed that cardiac muscle hypertrophy is a useful physiologic 
adaptation, which develops when an increased workload is chronically imposed on the 
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myocardium. Although the hypertrophied myocardium may allow maintenance of adequate 
cardiac compensation for many years, eventually it becomes incapable of meeting the 
increased workload imposed upon it, and heart failure ensues. For this reason, it has been 
suggested that myocardial hypertrophy may be considered the interface between the normal 
and failing heart (Grossman, Jones and McLaurin, 1975). In the next section, the mentioned 
transition between adaptive and maladaptive hypertrophy is explained in better detail.  
 
1.2.4 Stages and consequences  
In the 60s, Meerson and colleagues believed that hypertrophic transformation of the 
heart was divided into 3 stages. The first stage (or transient breakdown) involves the 
development of hypertrophy, in which load exceeds output. It is characterized by symptoms 
of left ventricular insufficiency leading to pulmonary congestion, hydrothorax, ascites and it 
can lead to death in some cases. In this stage cardiac dilation, inversion of the T wave with 
displacement of the S-T segment, swelling of heart muscle fibres, loosening of the myofibrils, 
and development of fatty dystrophy of the myocardium, among others, are observed. During 
the first four to five days, the weight of the heart increases at the rate of 10 to 12 per cent in 
each day; and the rate of protein synthesis in the myocardium increases about two-fold, as 
revealed by a metabolic label of cells (S-35 methionine). In this stage, a contractile 
insufficiency caused by acute cardiac strain and a deficiency in the activity of certain 
enzymes are also observed. Overall, this set of phenomena lead to the increase in CM weight, 
protein synthesis and loss of contractile force associated with cardiac hypertrophy (Meerson, 
1962; Frey et al., 2004). 
 The second stage is defined as the compensatory hypertrophy, in which the 
workload/mass ratio is normalized and resting cardiac output is maintained. At this time, 
almost all of the previous alterations on the physiology and functionality of the heart are 
restored, with exception of the heart weight (Meerson, 1962; Frey et al., 2004). It is 
characterized by the absence of cardiac insufficiency and of pulmonary congestion, 
hydrothorax and ascites; by arrest of enlargement of the heart; by disappearance of 
pathological modifications of the T wave and the S-T segments as well as by absence of signs 
of fatty dystrophy of the myocardium. Hypertrophy of muscle fibres and compact organization 
of myofibrils are apparent (Meerson, 1962; Frey et al., 2004). The weight of the heart is 
about twice that of the normal heart and remains stable and the rate of protein synthesis in 
the myocardium was shown to be normal, by the metabolic label (S-35 methionine). In 
summary, this stage is associated to hypertrophy of the myocardium in a large proportion, 
which gives rise to an adequate oxidation and oxidative phosphorylation, an inhibition of 
anaerobic resynthesis of ATP and a re-establishment to normal of creatine phosphate and 
glycogen content in the myocardium (Meerson, 1962; Frey et al., 2004). Furthermore, 
hypertrophy leads to a decrease of the number of capillaries and consequently to myocardial 
hypoxia, with accumulation of acid lactic. These changes are typical of the condition of the 
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heart during clinical compensation to cardiac failure and hypertension (Meerson, 1962; Frey 
et al., 2004).  
 The third stage is defined by the manifestation of heart failure, with ventricular 
dilation and progressive declines in cardiac output despite continuous activation of the 
hypertrophic program. It is characterized by the development of cardiac insufficiency, 
marked and continuously progressing myocardial fibrosis, the appearance of focal fatty 
degeneration, the deficit in DNA concentration in the myocardium that falls to 30 to 40 per 
cent of normal. It is also observed a decrease of 50 to 60 per cent in the rate of protein 
synthesis in the myocardium, through incorporation of S-35 methionine, and a decrease of the 
ATP level in the myocardium by 10 to 20 per cent. The others factors remain as stated in the 
second stage of this process. This period involves moderated hypoxia, which in turn leads to 
depression of the normal profile of protein resynthesis of the myocardial protein structure, to 
marked fibrotic response, and to decrease of contractile performance of the heart (Meerson, 
1962; Frey et al., 2004). The principal characteristics of each stage are summarized in Table 
II. 
 Table II - Characteristics of the 3 stages of the cardiomyocyte hypertrophy. 
 
1st stage 2nd stage 3rd stage 
Cardiac function 
Left ventricular 
insufficiency (pulmonary 
congestion, hydrothorax 
and ascites) 
Normal (absence of 
pulmonary congestion, 
hydrothorax and ascites) 
Insufficiency 
Fatty degeneration of 
myocardium 
Fatty degeneration of 
myocardium 
Myocardial fibrosis 
 
Twofold increase of protein 
synthesis in the 
myocardium 
 
Normal rate of protein 
synthesis in the 
myocardium 
 
50 to 60% decreased 
protein synthesis in the 
myocardium 
Myocardium contractile 
insufficiency 
- 
Decrease of contractile 
capacity of the 
myocardium 
Deficient heart's electric 
activity 
Normal heart's electric 
activity 
* 
Cardiac morphology 
Cardiac dilatation 
 
Arrest of cardiac dilatation 
* 
Heart weight increase 
 
Twofold heart weight 
increase 
* 
 *Remains the same as in the second stage 
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 The chain of events previously described lead to an ultimate phase (cardiac 
remodelling), which leads to failure, associated to functional perturbations of cellular Ca2+ 
homeostasis and ionic currents (Frey et al., 2004; Baba and Wohlschlaeger, 2008). This 
contributes to an adverse prognosis by predisposing to ventricular dysfunction and malignant 
arrhythmia (Frey et al., 2004; Baba and Wohlschlaeger, 2008). Although, at the beginning, 
the response of individual CMs to an increase workload is an adaptive hypertrophic growth 
(size, volume, mass) in order to reduce wall tension, if a continuous load is imposed, 
hypertrophy becomes a maladaptive process, leading to chronic heart failure and eventually 
to death (Frey et al., 2004; Baba and Wohlschlaeger, 2008). Dilation is followed by increased 
ventricular wall stress resulting in decreased coronary blood flow, impaired pump function 
and diminished cardiac output. Moreover, interstitial fibrosis is observed, further hindering 
systolic and diastolic cardiac function. Although the dichotomy between adaptive and 
maladaptive hypertrophy events are a long studied phenomena, mechanisms that determine 
the transition from the first to the second, and therefore, the transition to overt heart 
failure, are still poorly understood (Frey et al., 2004; Baba and Wohlschlaeger, 2008). Figure 
4 shows the main stages and characteristics of cardiac hypertrophy: 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 - Cellular basis for growth, hypertrophy, and failure of the human heart. This figure depicts various 
stages in the growth of the myocardium and the myocardial response to chronic stress (Buja and Vela 2008).  
 
1.3 Cardiomyocyte development 
The heart is hollow muscular organ composed by cardiac muscle (epicardium, 
myocardium, and endocardium) and connective tissue. Cardiomyocytes or 
myocardiocytes/cardiac myocytes (CMs) are binucleated or multinucleated cells that compose 
the myocardium being located at the walls. Cardiac muscle is one of the three major types of 
muscle along with skeletal and smooth muscle (Lee, 2010). Each CM contains myofibrils, 
which are long chains of sarcomeres, the contractile units of muscle cells. The CMs composing 
the myocardium, are responsible for the heart contraction and, therefore, for the heart’s 
blood pumping throughout the cardiovascular system.  
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 For more than 150 years, the heart regeneration was deeply studied and extremely 
controversial. Contradictive theories lead the discussion about the proliferation and self-
renewal of mammalian adult CMs (Laflamme and Murry, 2011).  
 
1.3.1 Embryogenesis 
During the mammalian embryogenesis there is extensive CM proliferation, which is 
essential for the heart construction and organization (Mollova et al., 2013). Shortly after 
birth, CMs undergo one last round of DNA synthesis without cytokinesis, resulting in the 
formation of mostly binucleated CMs. After this moment, cell cycle re-entry is blocked to the 
CMs, indicating a permanent cell-cycle withdrawal; cell division ceases and postnatal heart 
growth is achieved through hypertrophy of CMs (Lee, 2010; Ptaszek et al., 2012; Mollova et 
al., 2013). This switch in the growth potential of CMs, from a proliferative cell phenotype to 
an exclusively hypertrophic phenotype, occurs at different stages of development in different 
species. In the mouse it occurs at or shortly after birth, in the rat it occurs between 3 and 4 
days post-natally, whereas in humans, CMs do not divide after 7 months of age (Bicknell, 
Coxon and Brooks, 2007). This process of nuclear division without cellular division is a specific 
form of endoreduplication, called acytokinesis mitosis. This phenomenon is shared by the 
most part of the mammals, as a consequence of DNA replication without cell division, leading 
to binucleated CMs, although the degree of binucleation varies from specie to specie, and 
represented at Figure 5 (Lee, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 - Cardiomyocyte re-entry into the cell cycle by activating PI3K, leading to DNA synthesis and 
cytokinesis. However, most cardiomyocytes in mice become consequence of DNA replication without cell division 
(Xin, Olson and Bassel-Duby 2013). 
 
1.3.2 Adult transition 
Contradictive theories lead the discussion about the proliferation and self-renewal of 
adult cardiomyocytes, wherein it is hypothesized that they cannot perform such events 
because they are terminally differentiated, which involve two closely linked phenomena: 
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permanent withdrawal from the cell cycle and cell type-specific differentiation characterized 
by the upregulation of a panel of tissue-specific genes. For instance, fetal or neonatal rodent 
cardiac myocytes primarily express β-myosin heavy chain (β-MHC) and skeletal actin, but as 
cardiac myocytes undergo the process of terminal differentiation, these are downregulated 
and both α-MHC and cardiac actin upregulated (Laflamme and Murry, 2011). Consequently, 
although often used interchangeably in differentiated cell types, cell cycle exit and terminal 
differentiation are not synonymous. Usually, terminally differentiation is defined as the 
situation in which the majority of cells do not reenter the cell cycle in response to mitogens 
or normal physiological stress (Laflamme and Murry, 2011). Although cell cycle reentry occurs 
in CMs in response to stress or injury stimulus, there is cumulating evidence that it also occurs 
to a limited extent in the adult normal heart (Bergmann et al., 2009; Laflamme and Murry, 
2011). Studies have suggested that entrance of human CMs into the cell cycle after 
myocardial infarction is transient and limited and that, as opposed to cytokinesis and 
proliferation, it leads to endoreduplication (increased DNA per nuclei or increased nuclei per 
myocyte) (Ahuja, Sdek and Maclellan, 2007). Endoreduplication may account for the 
discordance between the observed regenerative capacity of the heart after injury and that 
proposed based on pathological examination of cycling myocytes (Ahuja, Sdek and Maclellan, 
2007; Ptaszek et al., 2012). 
Others believe that the existence of cardiac stem cells or cardiac progenitor cells 
(CPCs) are responsible for CM proliferation associated with active mitotic processes 
accompanied by cytokinesis, resulting in a significant turnover and self-renewal of these cells 
after heart injury (Ahuja, Sdek and Maclellan, 2007). Most recently, the debate regarding the 
biological basis for CM renewal has undergone a major shift based on the recognition of the 
importance of stem cells in the biology of all organs of the body. These stem cells are 
recognized by the properties of continuous self-renewal and the potential for the production 
of a wide range of cellular progeny (self-renewing, clonogenic, and multipotent cells) (Buja 
and Vela, 2008). There is now evidence that stem cells from the bone marrow gain access to 
the circulation and migrate to other sites of the body during fetal development and likely 
contribute to the primitive cell population of multiple organs. These stem cells are localized 
to specialized regional environments referred to as niches (Pagliari et al., 2011). These 
various populations of stem cells are now considered to be an important source of cells and 
could be involved in limited CM turnover and renewal (Pagliari et al., 2011). Thus, in a 
paradigm shift, there is increasing recognition that the heart is a self-renewing organ. 
However, once committed to the myocyte lineage, the progeny of the stem cell can only 
undergo three to four rounds of cell division before permanently withdrawing from the cell 
cycle (Ahuja, Sdek and Maclellan, 2007; Pagliari et al., 2011). Thus adult hearts, regardless of 
species, are likely composed of predominantly terminally differentiated myocytes that do not 
reenter the cell cycle, with a minority of myocytes or resident stem cells that are capable of 
some limited cell cycle reentry (Ahuja, Sdek and Maclellan, 2007; Pagliari et al., 2011).  
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1.4 Pluripotent and multipotent stem cells for disease modeling  
 The stem cell field can be conceptually organized into work involving endogenous and 
exogenous cells. The many exogenous cell types can be further divided into pluripotent cells 
(such as embryonic stem cells, ESCs, and induced pluripotent stem cells, iPSCs) and 
multipotent cells of more limited potential (such as CPCs) (Laflamme and Murry, 2011).  
 For a cell to be considered pluripotent it needs to meet some requirements such as 
the ability: (1) to produce benign tumors (teratomas) in immunodefficient mice, which should 
consist of tissues arising from all three embryonic germ layers, such as cartilage, muscle, 
primitive neural cells and gastrointestinal tract tissue; (2) to generate chimeras, which 
demonstrates that cells can convey their genetic information to the next generation, assuring 
germline transmission (3) to express a set of specific markers associated with cell 
pluripotency (Freund et al., 2010; Bianco et al., 2013). Multipotency covers the above 
mentioned parameters, except for the first, since these cells are restricted to a limited range 
of cell types that they can give rise to (Freund et al., 2010; Bianco et al., 2013). 
 Since adult CMs are terminally differentiated and primary CMs cannot be maintained 
in cultured for long periods of time, stem cells offer a promising alternative for in vitro 
studies and generation of cardiac disease models, by allowing efficient and unlimited 
generation of CMs (although their differentiation appears to arrest at a fetal-like stage) 
(Beqqali et al., 2009). Although animal models can better simulate the in vivo events 
associated to the heart hypertrophy, they lack of predictability when translating its 
mechanisms to human models (Musunuru, Domian and Chien, 2010). 
  
1.4.1 Human embryonic stem cells 
The term “embryonic stem cell” was introduced in 1981 to distinguish embryo-derived 
pluripotent cells from teratocarcinoma-derived pluripotent embryonal carcinoma (EC) cells 
(Martin, 1981). First ES cells were derived from mouse inner cell mass (ICM) in the same year, 
(Evans and Kaufman, 1981) and in 1994, Bongso and co-workers reported the successful 
isolation of human ICM cells and their continued culture for at least two passages in vitro 
(Bongso et al., 1994). The first permanent human embryonic stem cell (hESC) lines were 
derived more than a decade ago by Thomson and co-workers (Thomson et al., 1998) and these 
lines are still widely used. 
HESCs are capable of proliferating extensively at undifferentiated state in vitro and 
have the ability to differentiate towards all three germ layers and furthermore can, in 
principle, give rise to all cell types of the body. This proliferative capacity makes these cells 
a powerful resource but it is also their disadvantage. Teratomas (benign tumors) are probably 
the most substantial risk associated to ESC-based therapies, and have been reported following 
transplantation (Wakitani et al., 2003). Moreover, ESC-based therapies are allogeneic and 
require immunosuppression drugs. HESCs are usually derived from the ICM of the 
preimplantation-stage blastocysts that can later be differentiated into the different cell types 
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present in the human organism (Boheler et al., 2002), as represented in Figure 6. Different 
embryonic cell lines can also be derived from the  morula (Strelchenko et al., 2004) or even 
from late stage (7-8 days) preimplantation embryos (Stojkovic et al., 2004). This contributes 
to the ethical controversy surrounding their use. HESC express transcription factors and 
surface markers associated with an undifferentiating stage, such as Octamer-4, POU domain, 
class 5, transcription factor 1 (Oct4), Nanog, Sex determining region Y-box 2 (Sox2), stage 
specific embryonic antigen 4 (SSEA-4), tumor-related antigen 1-60 (TRA-1-60) and TRA-1-
81(Hoffman and Carpenter, 2005). Telomerase and alkaline phosphatase activity of hESCs is 
high and the karyotype should be normal and remain unaltered during extended culture 
periods (Hoffman and Carpenter, 2005). 
Figure 6 - Pluripotent, embryonic stem cells originate as inner mass cells within a blastocyst. The stem cells can 
become any tissue in the body, excluding a placenta. Only the morula's cells are totipotent, able to become all 
tissues and a placenta. (Jones, 2006) 
  
 In vitro differentiation of ES cells normally require an initial aggregation step that 
result in the formation of embryoid bodies (EBs) that spontaneously differentiate into the 3 
primary germ layers (endoderm, ectoderm and mesoderm) (Wobus, Wallukat and Hescheler, 
1991; Kehat et al., 2001) and can be further stimulated towards the cardiac lineage by 
combinatorial addition of several factors from the Wnt, BMP, TGFβ and FGF families (Beqqali 
et al., 2009). Cardiomyocytes are readily identifiable, because within 1 to 4 days after 
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plating, they spontaneously contract. With continued differentiation, the number of 
spontaneously beating foci increase, and all the EBs may contain domains of beating cells. 
The rate of contraction within each beating area rapidly increases with differentiation, 
followed by a decrease in average beating rate with maturation. During early stages of 
differentiation, CMs within EBs are typically small and round (Wobus, Wallukat and Hescheler, 
1991; Boheler et al., 2002). The nascent myofibrils are sparse and irregularly organized or 
lacking, whereas others contain parallel bundles of myofibrils that show evidence of A and I 
bands. Adjacent CMs often show different degrees of myofibrillar organization. With 
maturation, ES cell–derived CMS become elongated with well-developed myofibrils and 
sarcomeres. Beating cells are primarily mononucleated and rod-shaped (Boheler et al., 2002). 
They contain cell-cell junctions consistent with those observed in CMs developing in the 
heart. During terminal differentiation stages, densely packed well organized bundles of 
myofibrils can be observed, and the sarcomeres have clearly defined A bands, I bands, and Z 
disks. (Boheler et al., 2002) Overall, the length, diameter, area, structure and architecture of 
ESC-derived CMs resemble that reported for fetal-to-neonatal rodent myocytes, although they 
can never reach the level of development of adult CMs (Boheler et al., 2002). 
1.4.2 Induced pluripotent stem cells 
The cloning of the first mammal, “Dolly” the sheep, demonstrated that nuclei from a 
differentiated cell can be reprogrammed into undifferentiated state (Wilmut et al., 1997). 
The cloning of Dolly was achieved by a technique called somatic cell nuclear transfer (SCNT), 
where the oocyte nucleus is replaced by a nucleus derived from a somatic cell. In principle, 
embryonic stem cells can also be derived from embryos produced by SCNT enabling the 
production of patient specific hESC lines. However, this technique has major ethical 
reservations, since human embryos would be produced only for ES cell production and a large 
number of human oocytes would be needed. In addition, many countries have prohibited 
human cloning by law (Yamanaka, 2008). 
The technology to reprogram somatic cells to pluripotent stem cells (induced 
pluripotent stem or iPS cells), for the first time described in 2006 by the Japanese group 
headed by Yamanaka, had a major impact on the field of stem cell biology. Similar to hESC, 
human iPS cells have the potential to differentiate to any cell type of the human body, 
including cardiomyocytes. The advantage is that generation of iPS cells do not include embryo 
manipulation and destruction, and they could be used in autologous therapies without 
immune rejection since they can be derived from the patient's own somatic cells (Laflamme 
and Murry, 2011). Since iPS cells can be derived from specific groups of patients, it may be 
important for human disease modeling, since they carry the patient's genetic material 
(Beqqali et al., 2009). The disease modeling process regarding these cells are schematized in 
Figure 7. 
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Figure 7 - Human disease modeling by extraction of patient's own cells, reprogrammation and differentiation 
into specific cells. (Adapted from Cincinnati Children's Hospital Medical Center, 2011) 
 
  HESC contain factors that can induce reprogramming of somatic cell nucleus (Cowan 
et al., 2005, Allegrucci et al., 2007). Therefore somatic cell fusion with ES cell regenerates 
pluripotent cells. However, pluripotent cells obtained by fusion contain both chromosomes 
from the ES cell and from the somatic cell resulting in rejection if implanted (Yamanaka, 
2008). Nevertheless, the above-mentioned findings led researchers to search for factors that 
induce reprogramming. Finally, in 2006, Takahashi and Yamanaka discovered that by 
introducing four "pluripotency genes" (genes identified previously as being prominently 
expressed in ESCs: e Oct4, Sox2, Klf44 and c-myc) mouse embryonic as well as adult 
fibroblasts could be reprogrammed into pluripotent stem cells and able to form all cells in the 
body of an adult mouse (Takahashi and Yamanaka, 2006; Freund et al., 2010; Laflamme and 
Murry, 2011). The following year the same factors were used to make induced pluripotent 
cells (iPS cells) from human fibroblasts (Takahashi et al., 2007). Human iPS cells were also 
obtained, contemporaneously, by Thomson and co-workers, in 2007, by using Oct4 and Sox2 in 
combination with Nanog and Lin-28 homolog (Lin28) instead of c-myc and Klf4 (Yu et al., 
2007). Ever since, the development in this field has been very intensive and this technique 
has been designated as a major breakthrough in stem cell research. Recent developments in 
the field were registered in Netherland, by the Christine Mummery group, where human iPS 
cell lines were derived from skin fibroblasts and reprogrammed by retroviral overexpression 
of the four transcription factors Oct3/4, Sox-2, Klf4 and c-myc (Freund et al., 2010). After 
retroviral infection, colonies displaying the typical morphology of human embryonic stem 
cells emerged and proved self-renewal and differentiation in a wide spectrum of cell 
phenotypes when appropriately stimulated in culture, including CMs (Freund et al., 2010). 
Ever since, the development in this field has been very intensive and this technique has been 
designated as a major breakthrough in stem cell research. 
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1.4.3 Cardiac progenitor cells 
 Over the past decade, extensive studies have provided the evidence of a reservoir of 
cardiac stem/the cardiac progenitor cells (CPCs) (Messina, Giacomello and Marbán, 2007; 
Beqqali et al., 2009), within the adult heart, either derived in the heart or recruited from the 
bone marrow through the bloodstream (Di Nardo et al., 2010). Studies revealed that these 
endogenous cells express markers normally related to stem cells (c-kit, MDR-1 and Sca-1) and 
harbor telomerase activity, characteristics only related to “stemness”. (Barile et al., 2007; 
Guan and Hasenfuss, 2012) The in vivo evidence for the replicative feature of these CPCs was 
emphasized for the fact their number registered more than a 13-fold increase in the 
hypertrophic myocardium of heart disease patients, able to differentiate in CMs. (Barile et 
al., 2007) Contrariwise to what was previously considered, these evidences point for the fact 
that the heart is not completely terminally differentiated and instead is capable of limited 
proliferation. Although lineage tracing and isolation of these cells could already establish 
their identity and multipotency, protocols to reliably purify, expand and differentiate the 
CPCs are necessary for their practical use as disease models (Beqqali et al., 2009; Musunuru, 
Domian and Chien, 2010).  
 
1.5 Advances in cardiac disease characterization 
1.5.1 Extracellular matrix in cardiomyocyte differentiation 
 Cells are extremely influenced by the signalling cues originated from the extracellular 
matrix (ECM), which provides them with structural and biochemical support, and contributes 
not only to individual cellular but also to collaborative organ-level functions. In cardiac 
physiology, the ECM induces mechanical, electrical and chemical signals during development, 
homeostasis and injury. These signalling mechanisms modulate in cellular interactions and 
activities interactions, such as proliferation, migration, adhesion and changes in gene 
expression (Bowers, Banerjee and Baudino, 2010). The components of the ECM can either play 
an agonistic or antagonistic role, contributing to the progression towards either heart 
recovery or heart failure, during cardiac disease period (Miner and Miller, 2006). The 
understanding of the paradoxal relationship between cellular and acellular signals that are 
involved in cell-ECM interactions is vital for proper cell-cell communication and cell behaviour 
in the development of the heart (Miner and Miller, 2006; Bowers, Banerjee and Baudino, 
2010). The ECM also plays a fundamental role, particularly, during the embryonic 
development, by guiding stem cell differentiation into the different lineages, and, specifically 
in the heart, it is imperative the presence of these components so organ differentiation can 
occur. Different ECM components can selectively affect many types of signal transduction 
pathways that result in different cell response and behaviour (Streuli, 1999).  
 It has been shown that cells can be maintained in in vitro culture much more 
efficiently if they are supported on substrate components that closely resemble the ECM in 
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which they occurred in vivo (Baharvand et al., 2005). The establishment of adequate in vitro 
conditions, that mimic the in vivo differentiation process, still represents a challenge 
concerning the derivation of pluripotent cells into CMs. The ECM of CMs is primarily composed 
by: type I, II and III collagen; laminin, type IV collagen mainly (basement membrane); 
fibronectin, entactin and several proteoglycans, such as heparan sulphate, (pericellular 
membrane); and also proteinases (Farhadian et al., 1996; Pelouch et al., 1994). Combinations 
of these molecules would beneficiate the differentiation of stem cells into a state resembling 
native cardiomyocyte’s phenotype and genotype.  
 With the establishment  of ESCs cultures it became possible to study the 
differentiation of these pluripotent cells in vitro and the success in CM adhesion and 
development to the experimental surface and, as previously related, ECM components have a 
special role in this subject. In fact, it is expected that a balanced composition of specific ECM 
proteins and/or molecules ensure adequate adhesion and promote CM differentiation. Table II 
presents the most important ECM compounds and their function, which demonstrated positive 
results in the differentiation of ESCs into cardiomyocyte-like cells. 
 
Table III - Revision of the ECM components used for ESC differentiation and development into cardiomyocyte-like 
cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ECM component Function References 
Vimentin Cardiomyocyte flexibility Boheler et al., 2002 
Desmin Cardiac muscle formation Boheler et al., 2002 
β1-integrin 
Cardiac differentiation, expression of α-MHC and β-MHC, 
arrange of sarcomeric architecture 
Boheler et al., 2002 
Collagen I 
Mechanical stability, cell attachment, differentiation and 
angiogenesis 
Boheler et al., 2002; 
Horton et al., 2009 
Collagen IV 
cell-ECM adhesion, transmission of force during diastole 
and systole, binds to laminin 
Pelouch et al., 1994; Wu et 
al., 2010 
Laminin 
Cardiomyocyte adhesion, growth, proliferation, 
differentiation,  cardiomyogenesis, binds to collagen IV 
Bruggink et al., 2007 
Fibronectin 
Cardiomyocyte adhesion, proliferation, migration, 
differentiation, angiogenesis, binds to collagens and 
heparin 
Horton et al., 2009; 
Wu et al., 2010 
Heparan sulfate 
Developmental processes, angiogenesis, inhibition of 
AngII-induced hypertrophy 
Akimoto et al., 1996; 
Strunz et al., 2011 
Entactin/Nidogen-1 
(NID-1). 
Cardiomyocyte structural support and growth regulatory 
functions, crosslinking of collagens and laminins 
Grimm et al., 1998; 
Yurchenko and Patton, 
2009 
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1.5.2 Protein patterning 
 Protein pattern is a valuable tool to evaluate CM hypertrophy phenotype in vitro. 
Despite of guiding CM differentiation of ESCs, the patterns also allow size and shape control 
of the cells. It was recently shown that the imposed geometrical boundaries of the ECM 
proteins promote sarcomere alignment by altering the myocyte shape and directing the 
orientation of the myofibrillar network (Bray, Sheehy and Parker, 2008). Cells react to the 
patterns by architecturally reconfigure, reassemble and reorganize their contractile 
cytoskeleton in response to the geometrical cues in the ECM proteins (Bray, Sheehy and 
Parker, 2008). Since it is denoted morphology alterations in cardiac myocytes during 
hypertrophy and being these cells morphological inconstant, when in culture, it is necessary a 
procedure to control cell size and shape, in order to standardize those parameters. When size 
and shape conditions are imposed to these cells, a hypertrophic stimuli can be applied and 
morphological changes can be quantified, allowing a better understanding of the hypertrophy 
condition, associated to several heart diseases. Several techniques that have been developed 
to pattern proteins on planar substrates can be used to achieve such cell control and will be 
revised next. 
 
Photolithography 
 For many years, the semiconductor industry has developed and optimized the 
photolithographic methods to create high resolution features in semiconductors and metals. 
In photolithography, a substrate is coated with a photoactive polymer. When specific regions 
of this polymer are selectively exposed to UV light, the solubility of the exposed regions is 
altered, such that they can be dissolved while leaving the unexposed regions unaffected (or 
vice versa, depending on chosen photoactive polymer) (Britland et al., 1992; Lom, Healy and 
Hockberger, 1993). Further, this development step leaves portions of the underlying substrate 
exposed to modification, such as etching, doping, or metal coating. 
 More recently, these methods have been applied to generate protein patterns. In 
general, the substrate regions that have been exposed after the development step are 
functionalized in order to bind, or promote binding, of target proteins. For example, an 
exposed silicon dioxide surface may be covalently modified with an aminosilane, leaving a 
reactive amine group which can preferentially bind proteins (Britland et al., 1992; Lom, Healy 
and Hockberger, 1993).  
 Photolithography is a mature technology, optimized over many years by the 
semiconductor industry, and this extensive development makes it an attractive technique for 
microscale protein patterning. The resolution of these techniques is fundamentally limited, 
though, by the diffraction limit of the light used during exposure. Additionally, the harsh 
chemicals typically used limit the compatibility of the process with biological media, though 
progress has been made in the development of biocompatible photoresists (Douvas et al., 
2002). 
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Microcontact printing 
  Microcontact printing (µCP) is a form of soft lithography and is able to perform fast 
and efficient adhesive micropatterns of proteins that can be used to control individual cell 
shape and adhesion patterns. It is a stamping based method technique where a polymeric 
mold (stamp) is fabricated from a template (master) (Bernard et al., 1998; Xia and 
Whitesides, 1998; Kane et al., 1999; Quist et al., 2005; Ruiz and Chen, 2007). The process can 
be subdivided into three parts: fabrication of the master, micropatterned stamp fabrication 
and content deposition, as schematized on Figure 8 (Théry and Piel, 2009). To create the 
stamp, containing the microfeatures of interest for subsequent microcontact printing, the 
first step is to fabricate a master. The master is created from a silicon wafer and from the 
application of a photoresist mask on its surface. The wafer is spin coated so the photoresist 
coated the entire wafer. Then, it is exposed to UV light in the desired regions of 
photoresistance which are etched. The topography of the wafer is altered, according to 
regions that are exposed to the radiation, the final step of creating the master. From this 
template it is possible to obtain replicates (stamp), containing the microfeatures on the 
surface, by casting a PDMS solution onto the master, followed by baking it in the oven. 
Afterwards, the stamp can be removed from the master and is ready to be used. This process 
is schematized in Figure 8A. Subsequently, a drop of protein solution “ink” is deposited on the 
stamp, it is dried after a incubation period and it is brought into gentle contact with the 
substrate to be modified, as represented in Figure 8B (Bernard et al., 1998; Xia and 
Whitesides, 1998; Kane et al., 1999; Quist et al., 2005; Ruiz and Chen, 2007). The protein 
solution is transferred from the protrusions in the stamp to the substrate (Bernard et al., 
1998; Xia and Whitesides, 1998; Kane et al., 1999; Quist et al., 2005). In some cases the 
substrate requires to be spin-coated previously to the microcontact printing, depending on 
the type of substance that composes the material (e.g. substrates composed by silica such as 
glass). This arises from the fact that the wettability degree of the material needs to be 
enhanced for a proper ink bonding, which can be achieved by chemical activation of the 
substrate (Blinka et al., 2010). However, in the case of silica based materials it is required a 
complex chemical activation for a long-term stability, where another type of surface 
modification, such as Polydimethylsiloxane (PDMS) coating, by spin coating, can offer a better 
solution for being suitable for usual chemical activation (Griffin, 1954; Kaufmann and Ravoo, 
2010; Blinka et al., 2010). In brief, spin coating is a technique used for the application of thin 
films into a substrate surface, by depositing a small puddle of a fluid resin or a solution onto 
the center of a substrate and then spinning the substrate at high speed to thin the fluid and 
spread all over the surface (Théry and Piel, 2009). 
The use of a broadly biologically friendly polymer, PDMS, for the stamp material 
makes this technique highly biocompatible (Bernard et al., 1998; Xia and Whitesides, 1998; 
Kane et al., 1999). Depending primarily on the technique used to fabricate the initial 
template from which the stamp is generated, this technique is capable of features from 
hundreds of microns down to tens of nanometers (Csucs et al., 2003). Some disadvantages of 
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Cast a silicone replica from the silicone master 
this technique lie in the potential of the flexible polymeric stamp to generate deformed or 
distorted patterns, non-uniformity of coverage over the patterned area, and potential for 
surface contamination of the same (Torres et al., 2008). 
 
Figure 8 - Resumed microcontact printing process. (A) The steps involved in producing molds by photolithography 
and subsequent stamp (adapted from Gonzalez-Macia et al., 2010); in (B) is schematized the stamping process of the 
molecules of interest onto the substrate (coverslip) (adapted from Von Philipsborn et al., 2006). 
 
Dip-pen nanolithography 
 Patterning via dip-pen nanolithography is similar conceptually to writing using a quill 
and ink. An atomic force microscope (AFM) tip is dipped in an “ink” solution containing 
protein or a cross-linking molecule, which will bind protein in subsequent steps. The coated 
tip is then dragged across the substrate, leaving a trail of target molecule in the vicinity of its 
path, patterning directly on a variety range of substances. This technique is capable of very 
small feature sizes, down to tens of nanometers, and can conceivably place an arbitrary 
number of different protein types by using different ink solutions (Piner et al., 1999). Thus, it 
is one of the few existing methods that are capable of generating arrays with hundreds of 
features (Lee et al., 2006). However, due to its serial nature and the limited amount of “ink” 
that can be loaded on each loaded tip, this technique is slow and cannot easily generate large 
patterns. 
                    A                                                                           B 
                                                                                                       
 
Figure 7 - Resumed Microcontact Printing process: (A) the steps involved in producing molds by 
photolithography and subsequent stamp (Gonzalez-Macia et al., 2010).; in (B) is schematized the stamping process 
of th  molecules of interest onto the substrate (coverslip) (Von Philipsborn et al., 2006). 
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Ink-jet printing 
 The ink-jet printing of proteins makes use of a mechanism very similar to what one 
would find in a desktop ink-jet printer. It is a versatile technique widely used for the direct-
writing of two-dimensional features, and increasingly, for three-dimensional structures 
(Delaney, Smith and Schubert, 2009). It can be divided into two categories: drop-on-demand 
and impulse inkjet, whereby droplets are generated when required and patterned onto the 
substrate. Ink-jet printing can also be subdivided according to the mechanism mode in which 
the droplets are created, such as piezoelectric, thermal and electrostatic (Delaney, Smith 
and Schubert, 2009). In general, a protein-containing solution is loaded into a channel and 
pressure is applied on the fluid in the same channel, for example by expansion of a 
piezoelectric wall or rapid localized heating, causing a droplet of solution to be expelled onto 
a substrate (Pardo, Wilson and Boland, 2003; Roda et al., 2000; Barron et al., 2005). 
  This technique is relatively inexpensive, simple, and based on existing commercial 
technology. By placing the protein solution only in designated regions, the technique avoids 
problems associated with non-specific binding of target proteins outside of the desired 
region. Waste and contamination are reduced with this technique. Its primary disadvantage is 
that the feature size is generally limited to tens of microns (Barron et al., 2005).  
 
Self-assembled patterns  
A variety number of techniques have demonstrated that under certain conditions, 
molecules may self-assemble into distinct geometries. These shapes can be functionalized, 
generating protein patterns which follow the self-assembled geometries, or act as a mask for 
functionalization of the underlying substrate. For example, some groups have used micro- or 
nano-scale spheres which self-assemble into a close-packed pattern on a surface to create a 
colloidal mask. Biomolecules can be adsorbed in the interstices between the spheres, leaving 
a hexagonal pattern of the target biomolecule on the surface after the spheres are removed. 
Protein feature sizes down to tens of nanometers have been demonstrated with this 
technique (Cai and Ocko, 2005; Valsesia et al., 2006). 
 Other groups have used lattices of DNA tiles to create protein arrays. The sticky ends 
of the DNA tiles are engineered to self-assemble into a regular array. Periodic patterns of the 
protein streptavidin were demonstrated by Yan et al. by incorporating a biotin group in the 
center of each tile, giving a regular spacing between individual streptavidin molecules of 
approximately 19nm (Yan et al., 2003). By engineering multiple tiles which self-assemble into 
more complicated geometries, and incorporating biotin into only a portion of them, the 
spacing between streptavidin molecules can be modified (Park et al., 2005).  
 Bacterial membrane support proteins, S-layers, self-assemble into periodic lattices of 
various geometries, and have also been functionalized to serve as a scaffold to generate 
regular periodic patterns of biomolecules such as streptavidin, with individual proteins 
arrayed with approximately 10nm spacing (Sleytr et al., 2007).  
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 Broadly, these self-assembly techniques are capable of generating periodic patterns 
with extremely small feature sizes over wide areas. However, it is a quite rudimentary 
technique that limits the variation and control of the resultant geometries. The feature size 
and spacing over the entire patterned region are predetermined by the choice of templating 
molecules or particles (Sleytr et al., 2007). 
 
1.5.3 High-throughput bioimaging systems 
 Recently, the combination of the High-Throughput Screening (HTS) technology with 
High Content Imaging (HCI) has been arousing interest in the research community 
(Unterreiner and Gabriel, 2011). This evolution was possible mainly due to the hardware 
improvements of the automated microscopes, as the auto-focusing, as well as the 
enhancement of the image analysis software enabling fast data acquisition saving both time 
and costs in the screening process (Zanella, Lorens and Link, 2010; Unterreiner and Gabriel, 
2011; BD Biosciences, 2007) HCI can be characterized by the use of fluorescent label 
techniques to track phenotypic alterations in cells (Zanella, Lorens and Link, 2010). It enables 
simultaneous assays of multiple cellular targets allowing the extraction of numerous features 
within a single experiment (Zanella, Lorens and Link, 2010; BD Biosciences, 2009) It provides 
cellular or sub cellular resolution and generates data in a fast fashion.  These assays can give 
different insights of the compound’s action as well as their unspecific effects (e.g. toxicity) 
(Unterreiner and Gabriel, 2011; BD Biosciences, 2007; BD Biosciences, 2009) The disadvantage 
of this technique relies on the limited throughput that can be offered, due to the complexity 
of the HCI assays (Unterreiner and Gabriel, 2011). For the other hand, automated HTS assays 
are able of performing fast screenings and of fast data acquisition of multiple compounds 
simultaneously but with limited resolution, relevant for biological and chemical fields 
(Unterreiner and Gabriel, 2011; Major, 1998; Macarron et al., 2011; Martis, Radhakrishnan 
and Badve, 2011). High-Throughput HCI assays are the resulting combination of both worlds 
enabling fully automated primary screenings of large amount of samples with high resolution 
acquisition in multiplexed mode (Unterreiner and Gabriel, 2011). In Table IV it is revised 
some of the commercially existing bioimaging systems and some characteristics:  
 
 
 
 
 
 
 
  
22 
 
Table IV- Available high-throughput bioimaging systems. (Adapted from Comley, 2005; Zanella, Lorens and Link, 
2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5.4 Cellular phenotypic characterization  
 For decades, the visualization of cells on the microscopy was the primary method for 
cell identification, characterization and function (Carpenter et al., 2006). While nothing can 
fully replace the expertise of an experienced biologist, observing a vast set of samples by eye 
is a time-consuming, subjective and non-quantitative (Lamprecht, Sabatini and Carpenter, 
2007) and nowadays that method substituted. By fluorescently label specific proteins or 
antigens of cells, by immunocytochemistry techniques, they can be localized with the 
detection of the different wavelengths associated to the dyes coupled to the secondary 
antibody used in this cell staining technique (Rojo, Bueno and Slodkowska, 2009). The 
different cell stainings can be detected by HCI systems, mentioned in the previous 
subsection, and stored as an image format (Unterreiner and Gabriel, 2011). Software for 
image analysis are available using specific algorithms that can automatically analyze specific 
features of images, providing several advantages, such as, speed, quantitative and 
reproducible results and simultaneous measurement of a huge variety of cell features 
(Lamprecht, Sabatini and Carpenter, 2007; Kamentsky et al., 2011).  Currently, innumerous 
image analysis software are commercially and freely available.   
 The open-source ImageJ, Image-Pro Plus and the Metamorph® are image processing 
programs able to read several image formats, perform several enhancing operations to them, 
Company Brand name Light source Optics* 
Amnis ImageStream Laser/Arc lamp WF 
BD Biosciences BD Pathway 855 Arc lamp WF/CF 
BD Biosciences BD Pathway 435 Arc lamp WF/CF 
GE Healthcare IN Cell Analyzer 2000 Arc lamp WF 
Intelligent Imaging Innovations 3i Marianas Arc lamp WF 
Leica Microsystems TCS SP5 Laser CF 
Molecular Devices ImageXpressULTRA Laser CF 
Molecular Devices ImageXpressMICRO Arc lamp WF 
Olympus Scan^R Arc lamp WF 
Perkin Elmer Opera Laser CF 
Perkin Elmer Operetta Arc lamp WF/CF 
Thermo Scientific Cellomics ArrayScan VTI Arc lamp WF/CF 
Thermo Scientific CellWoRx Arc lamp WF 
TTP Labtech Acumen eX3 Laser WF 
*Abbreviations: CF, confocal microscope; WF, wide field. 
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to perform some quantity analysis, such as cell counting, and still remain very flexible 
(Lamprecht, Sabatini and Carpenter, 2007; Schneider, Rasband, Eliceiri, 2012). Custom-made 
programs can be added to this software and be used to measure different cell features (e.g. 
area and pixel intensity) (Lamprecht, Sabatini and Carpenter, 2007). CellProfiler is an open-
source platform for automated image analysis with several integrated cell measurements 
available, such as size, intensity and texture of fluorescent stains. (Lamprecht, Sabatini and 
Carpenter, 2007) Overall, these programs assemble characteristics, which are useful for 
phenotype characterization of determined cell types. 
 As referred previously, the cardiomyocyte hypertrophic phenotype is characterized by 
an increase of cell size and sarcomeres. Cell area measurements are the golden-standard 
method for the assessment of hypertrophy phenotype, in vitro, since it is the easiest type of 
feature that can be monitored (Dorn II, Robbins and Sugden, 2003). Sarcomere expression can 
also be monitored by evaluating the average pixel intensity within each cardiomyocyte. 
1.6 Thesis overview 
 The herein dissertation reports the experimental design and the results obtained 
while attempting to create more suitable assays for the understanding of cardiomyocyte 
hypertrophy, a critical precursor to the progress into heart failure. This work was performed 
during an internship in the Leiden University Medical Center (LUMC), Leiden, Netherlands, 
under the supervision of Dr Robert Passier and Marcelo Ribeiro (PhD-student).  
 As stated before cardiomyocyte hypertrophy is a major determinant for cardiac 
disease and therefore it is important to understand the underlying mechanisms for cardiac 
hypertrophy and to identify druggable targets that may lead to new therapeutic approaches. 
Overall, we set out to replicate in vitro cardiomyocyte hypertrophy and thus to establish a 
system for modelling and further dissecting the disease mechanisms. Concomitantly, we went 
further to generate tools for specifically easing the phenotypic characterization of 
hypertrophied cardiomyocyte-like cells. A platform was designed and constructed by the use 
of a bottomless 96-well plate and the attachment of a protein patterned custom-made 
coverslip, acquired to specifically fit the bottom of the plate. The coverslips were patterned 
with a protein solution (initially a fibronectin solution) through the microcontact printing 
technique, before being attached to the plate. Following the platform attachment, ESC-
derived cardiomyocytes were cultured on it and permitted to adhere to the fibronectin 
pattern, assuming their shape and orientation. Later on, other ECM proteins were tested 
alone and in combination to obtain the best CM adherence and development. Meanwhile, 
specific stimuli known to produce a hypertrophic effect on CMs were added to their 
environment. With the hypertrophic treatments the CMs suffer a morphological alteration, 
such as an increase in area, which is standardized by their adherence to the protein patterns. 
Cardiomyocytes grow in an irregular form and the protein patterns have the function to guide 
and lock the orientation and geometrical parameters of the cell growth. This intended to 
allow a more precise area measurement of the CMs and also to improve the readout for other 
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measurements, e.g. sarcomere intensity and elongation. These measurements were 
performed through the analysis of the images taken by the high throughput imaging system BD 
Pathway 855.  
 Considering that the existent techniques to evaluate the CM hypertrophy are still very 
ineffective and time consuming, this platform emerged from a need to optimize the process. 
Chapter 2 Materials and Methods 
2.1 Construction of the hypertrophy platform 
2.1.1 Coverslip characteristics 
 Two types of coverslips were used: one made of a polycarbonate optical grade 
plastic, Lexan, (RD477624 – Hybrislip, Grace Bio-Labs) and the other made of glass material 
(NEXTERION® Coverslip custom, #4; Glass: D263; Edge finishing: cut; Cleaning level: 
uncleansed). Both of them were custom-made to possess specific dimensions, 110mm x 
75mm, although with different thicknesses, 0.25mm and 0.50mm, for the glass and plastic 
coverslips, correspondingly. The two different coverslips required different methodologies 
and handling. While glass coverslips entail the need to be spin coated with a PDMS solution 
(as described in the next subsections) for subsequent microcontact printing, the plastic 
coverslips do not necessitate spin coating, and instead, microcontact printing can be 
performed directly. 
 
2.1.2 Spin coating 
 A polydimethylsiloxane (PDMS) solution was prepared by mixing a polymer base and a 
curing agent (two-component, Dow Corning Sylgard 184) at a 10:1 mass ratio. The PDMS 
solution was centrifuged at 3000 rcf for 3 min in the Rotina 48R (Hettich) apparatus to 
remove air bubbles (Kroetch, 2004; Dow Corning Corporation, 2005). When the liquid was 
properly degassed it was ready to be poured. 
 The custom-made glass coverslips were spin-coated with the Laurell WS-650MZ-23NPP 
spin coater, after a cleaning process of the substrates with sonication in ethanol and dried by 
shortly submitting the substrate through a Bunsen burner. Different spin coating programs 
were designed and tested to efficiently coat such substrates with PDMS. The coverslip was 
placed on top of the chuck and the vacuum was turned on to fix the coverslip into it and then 
the PDMS solution was gently deposited on top of it, with a Pasteur pipette. Once this step is 
accomplished the program is started and the PDMS solution is spread all over the coverslip, 
which becomes covered with a soft layer of this hydrophobic polymer at the end of the 
procedure. 
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2.1.3 Stamp fabrication  
A stamp was produced from a pre-existent master by casting a PDMS solution onto the 
master, which then was baked on the oven at 40 ºC for 1 hour. The PDMS solution was 
produced by mixing PDMS 527 (Dow Corning) part A with part B in a 1:1 mass ratio. After 
solidification, the PDMS was removed from the master, originating a negative copy of the 
micropatterns (lines) inscribed on the master. A stamp with approximately 60x40mm and lines 
inscribed with 20µm of width was produced. 
2.1.4 Microcontact printing 
 Fluorescence fibronectin (FFN) was produced through mixing 200µl of 8M Guanidine 
Hydrocholoride (G3272 - 100G), 200µl of 1mg/ml fibronectin (FN; BD Biosciences fibronectin 
from human plasma) and 10µl of Alexa Fluor 546 Maleimide dye (Invitrogen). The resulting 
solution was incubated for 1h, and then loaded into a syringe and injected into a dyalisys 
membrane (Slide-A-Lyzer Dialysis cassette Prod#66333; Thermo Scientific). The membrane 
was placed between a floating pouch (Slide-A-Lyzer Bouys; Thermo Scientific) in phosphate 
buffered saline (PBS) solution overnight. Afterwards, the solution was taken from the 
membrane and divided into aliquots for further use. 
 A FN/FFN solution was prepared from a mixture of 1mg/ml FN and 0,5mg/ml FFN in a 
1:1 ratio, which were diluted in distilled water in order to obtain a final concentration of 50 
µg/ml and stored away from the light. Drops of FN/FFN solution were deposited onto the 
stamp, assuring that the entire surface would be totally covered. The stamp was left in 
incubation for 30 minutes (or 1 hour if it was the first usage of the stamp) so the fibronectin 
could adsorb to the surface.  
Meanwhile, the substrate (coverslip) was chemically activated by being exposed to 
plasma radiation in a remote plasma reactor, to avoid direct bombardment of the surface, 
between 20 and 30 mA for 30 seconds (Lopera and Mansano, 2012). Plasma treatment was 
performed to raise the surface energy of the material, and in turn increasing also its 
wettability, improving its bonding characteristics regarding a posterior inking. Afterwards, 
the coverslip was immediately stored in a covered Petri dish to avoid contamination. 
Then, the fluorescence-labeled FN solution was aspirated from the stamp, which was 
immediately dried with nitrogen gas. Finally, the micropatterned face of the stamp was 
placed in contact with the substrate (coverslip) and gentle pressure was applied in it. After 1 
minute, the stamp was removed and the FN micropattern was printed on the coverslip. 
 
2.1.5 Attachment process 
Spin coating and microcontact printing techniques, above described, were combined 
in order to obtain protein micropatterns in the glass coverslips. As stated before, the protein 
micropatterns can be obtained directly by microcontact printing, regarding the plastic 
coverslips. This construct will be used for cell culture, enabling control of cell’s shape and 
orientation. 
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 Since coverslips had the same dimensions of the bottom of the bottomless 96-well 
plates, they could fit and be attached to these well plates. For this procedure, High-Vacuum 
Grease (Dow Corning) was used, which was carefully spread with a syringe onto the bottom of 
the plates. This silicone lubricant was chosen as glue because of its biocompatibility and 
effective sealing capacity. After assuring that the entire spaces between the wells were filled 
with this glue, the patterned side of the coverslip was placed in contact with the bottom of 
the plate, and a uniform pressure was applied with a cylinder roll. In an attempt to optimize 
this time-consuming process, a double sided tape (0,13mm thick adhesive film, 3M) was used 
in alternative, so that one of it sides could be attached to bottom of the well plate and the 
other attached to the coverslip.. However, it was necessary to cut circular holes in the tape 
with the same diameter and position of the wells, so the coverslip could be overlapped and 
fill those wells.  
2.2 Cell culture 
 
2.2.1 Origin of cell lines and ethical approval 
To enable purification and characterization of the hESC-derived cardiomyocytes, 
sequences encoding enhanced GFP (eGFP) were introduced into the NKX2-5 locus by 
homologous recombination, giving origin to the NKX2-5eGFP/w hESC line (Elliott et al, 2011). 
These cells can be either differentiated as embryiod bodies or by culture with END2, 
developing GFP+ contractile areas by day 8-9. (Elliott et al, 2011) The hESC line used with the 
targeted NKX2-5eGFP/w was the HES-3 and it was first derived in the ES Cell International Pte 
Ltd. - hES Cell Provision (Singapore). This cell line was generated by isolation of the inner cell 
mass, developing teratomas upon inoculation beneath the testis capsule of SCID mice. 
(Reubinoff et al, 2000) It was derived with the donor’s informed consent and approved by the 
Institutional review board.  
2.2.2 HESC-derived cardiomyocytes handling 
HESC-derived cardiomyocytes already in a differentiated state, through spin EB 
method, were acquired directly from Pluriomics (Pluricyte-Cardiomyocyte, NKX2-5eGFP/w line). 
They are frozen at day 14 of differentiation and it is advised to thaw them in 37 degrees 
waterbath for 4 minutes. They were gently transferred to a 50ml falcon tube and it was 
added 1ml of Cardiomyocyte medium (Pluriomics) at RT drop by drop every 4-6 seconds while 
gently swirling the cells after each addition. Another 1ml of Cardiomyocyte medium was 
added to the cardiomyocytes in the same drop-wise fashion while swirling the cells. Then, 
3.7ml of Cardiomyocyte medium was added drop by drop every 2-4 this time, while swirling 
the cells. They were spun for 3 minutes at 1100rpm and resuspended in appropriate amount 
of Cardiomyocyte medium, depending on plating conditions. A sample of the cell suspension 
was taken and diluted in a 1:1 ratio of Trypan Blue (Sigma-Aldrich). The sample was then 
transferred to a Neubauer Chamber for cell counting purposes. Cells were finally plated at 
the desired density. 
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2.3 Cardiomyocyte hypertrophy experiment 
2.3.1 Matrigel and fibronectin preparation 
 BD MatrigelTM Matrix Growth Factor Reduced (GFR) (BD Biosciences) was thawed by 
submerging the vial in ice at 4ºC. Once it was thawed, the vial was swirled to ensure that the 
material was evenly dispersed. Tips, tubes and medium were pre-cooled before in contact 
with BD MatrigelTM Matrix GFR. It was diluted in 1/10 using serum-free cell culture medium 
DMEM-F12 (Gibco®). A volume of 50µl of the diluted BD MatrigelTM Matrix GFR was added to 
each well. The plate was then incubated at RT for one hour before use.  
 Fibronectin 1mg/ml stock was thawed in ice and diluted in distilled water to a 
concentration of 20µg/ml. Wells from 96-well plates were coated with 50µl of the diluted 
fibronectin solution. The plate was incubated at room temperature for one hour before use. 
2.3.2 Hypertrophy induction in Matrigel and fibronectin 
After purification steps, through centrifugation of the collected EBs, they were 
dissociated with TrypLE to obtain single cells. MEF was added to the solution containing the 
EBs in a fourfold proportion, regarding the volume added of TrypLE. The solution was 
centrifuged again and resuspended in BPEL. Cardiomyocyte medium was later used instead of 
BPEL. Posteriorly, these above mentioned steps were instead performed by Pluriomics 
because of the direct acquisition of the Pluricyte Cardiomyocytes. Cardiomyocytes were 
plated in Matrigel- and 20ug/ml fibronectin-coated 96 well-plates, at 5, 10 and 20 cell/well 
densities, together with Cardiomyocyte medium and changed to Maturation medium after 1 
day.  
After three days of incubation period the hypertrophic stimulus 1µM ISO, 10µM PE and 
5% FCS, were added to the plated CMs. The treatments were refreshed ounce, after 2 days 
from the initial treatment and the total duration of the experiments were of 7 days.  
2.3.3 Hypertrohpy induction in fibronectin patterns 
After observation of the cardiomyocyte’s behavior on the different substrates it was 
used the constructed platform, with the fibronectin patterns printed on the bottom of the 
wells of the 96-well plates. hESC-cardiomyocytes (already differentiated from Pluriomics) 
were seeded on these plates by the same methodology described in the previous subsection, 
although a pre-step procedure was added to the protocol in the attempt to improve 
cardiomyocyte adaptation to the fibronectin. Cardiomyocytes were firstly seeded onto a 20 
μg/ml fibronectin coated 6-well plates with Cardiomyocyte medium and changed to 
Maturation medium 1 day after. The cells were refreshed at day 3 with Maturation medium 
and at day 7 the medium was aspirated and 1ml/well of TrypLE added. They were incubated 
for 10min and detached from the wells by pipetting up and down. It was added 4ml MEF for 
each ml of Tryple, transferred to a tube and spun down at 1100rpm for 3min. The supernatant 
was aspirated and the cells were resuspended in Maturation medium. After counting, the 
cardiomyocytes were seeded at 10 and 15 cells/well densities onto the plates with fibronectin 
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patterns, together with Maturation medium. Hypertrophic treatments, 1µM ISO, 10µM PE and 
5% FCS, diluted in Maturation medium, were added to the cardiomyocytes at day 10. The 
treatments were refreshed at day 12 and cardiomyocytes were fixed at day 14. 
2.4 ECM protein combination 
2.4.1 Monolayer coating 
 A combination of proteins, similar to the composition of Matrigel, was prepared which 
contained fibronectin, laminin (from Engelbreth-Holm-Swarm murine sarcoma basement 
membrane, aqueous solution, Sigma-Aldrich) and collagen IV (from human placenta Bornstein 
and Traub type IV, lyophilized powder, Sigma Aldrich) at different concentrations. To obtain 
the optimal concentration for each component an experiment was designed, in which every 
possible combinations of the protein at concentrations of 10, 20 and 50 µg/ml each were 
tested, resulting in a total of twenty seven different combinations. 
  To obtain solutions at the pre-defined concentrations, fibronectin and laminin were 
diluted in distilled water, while collagen IV was incubated overnight in a 0.25% acid acetic 
solution to reconstitute the lyophilized powder and then diluted in distilled water. The 
combinations and also the individual proteins at the different concentrations (controls) were 
used to coat wells from a 96-well plate and incubated at RT for two hours. HESC-derived 
cardiomyocytes were seeded onto these wells at the density of 5000 cells/well with 
Cardiomyocyte medium, and changed to Maturation medium after 1 day. The experiment had 
the duration of 7 days and the medium was refreshed twice. 
2.4.2 Protein patterns 
 It was prepared two mixes of the combined solution composed by fluorescence 
fibronectin, fibronectin, laminin and collagen IV. One with a final concentration of 20 µg/ml 
(each protein solution at 20 µg/ml) and the other of 50 µg/ml (each protein solution at 50 
µg/ml), being the last concentration based on Rodrigez and colleagues (2014) studies, 
although the three proteins were not used in combination in this article. The microcontact 
printing technique was performed as described before, and a platform was constructed with 
patterns of combined proteins printed on the bottom of the wells. HESC-derived 
cardiomyocytes were seeded onto these wells at the density of 10000 cells/well with 
Cardiomyocyte medium. In this experiment two controls were used to evaluate the 
cardiomyocyte response to the different medium. It was used Cardiomyocyte medium and a 
mix of this medium with Maturation medium, by changing to the last after one day. The 
above-mentioned hypertrophic treatments were started at day 3 and refreshed at day 5 with 
a total duration of the experiment of 7 days.  
2.5 Immunocytochemistry 
Cells were fixed with 4% Paraformaldehyde in PBS solution for 30 minutes and 
permeabilized with 0.1% Triton X-100 for 8 minutes, both at RT. Afterwards, they were 
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washed 3x5 min with PBS and blocked in 4% Normal Goat Serum (NGS) for 1 hour. After these 
steps, the cells were labeled with a mouse anti-rabbit α-actinin (sarcomeric) (Sigma, 1:800) 
and diluted in PBS containing 4% NGS. The primary antibody solution was removed after 1h 
and the cells were washed 3x10min with PBS and 0.05% Tween20. They were then labeled 
with donkey anti-mouse Alexa 488 (Invitrogen, 1:250) conjugated secondary antibody, after 
3x10 min washings with PBS and 0.05% Tween20. Secondary antibody was diluted in PBS 
containing 4% NGS and incubated for 1h at RT. Afterwards, the cells were washed 3x10min in 
PBS and 0.05% Tween20 and cell nuclei were visualized through DNA staining with DAPI 
(Sigma; 1:1000) diluted in PBS. Images were acquired with the BD Pathway 855 (BD 
Biosciences) and posterior image analysis was conducted.  
2.6 Image analysis 
 In this work, the BD Pathway 855 Bioimaging system was used, which is a high-content 
cell analyser that combines superior image quality, flexible image capture, and live-cell 
analysis to address a wide range of applications. It provides fluorescence intensity 
measurements, kinetic imaging, and morphological analysis, including subcellular imaging. A 
binocular eyepiece allows for direct viewing of cells in both fluorescence and transmitted 
light modes. This system has the ability to analyze multiple well-plate samples in an 
automated fashion, increasing the efficiency of the process by providing results in a fast 
manner. 
 Immunocytochemistry markers were combined in order to characterize further the 
phenotypic properties of hESC-CM culture in the hypertrophy state. Images from the 96-well 
plates with fixed and stained cells in it were taken with the BD Pathway 855 bioimaging 
system. The images were taken through the system’s automated and highly sensitive 
fluorescence imaging microscope with the 20x objective magnification. At this magnification 
level, the cardiomyocyte’s sarcomere structure and size could be easily detected and 
measured. Each well was automatically focused by the bioimaging system with its integrated 
laser autofocus. The laser autofocus was specifically calibrated and optimized for the 
acquisition settings that this work required. The different cell stainings were identified by 
specific channels that are able to detect the wavelength emitted from the different dyes 
coupled to the cells, previously mentioned. 
  Images taken to the CMs were acquired, processed with ImageJ software, and area, 
sarcomere intensity, cardiomyocyte ratio and elongation measurements were specifically 
designed and implemented on CellProfiller software, for this work. They were programmed 
and optimized by the bioinformatic Dr. Lu Cao, from the Embryology & Anatomy department 
in the Leiden University Medical Center (LUMC).   
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Chapter 3 Results 
3.1 Hypertrophy model construction 
3.1.1 Spin coating 
A PDMS coating was necessary for the custom-made glass coverslips in order to 
perform microcontact printing, but not for the plastic ones, as stated previously.  
 It is a very standard procedure to spin coat round and small coverslips and there are 
defined spin coating recipes for a complete, uniform and perfect coating of these substrates. 
However, the same cannot be stated for square, specially, for the high-dimension coverslips 
used in this work. These square coverslips were spin coated using the same recipe as advised 
for the round coverslips, but the results were not the satisfactory, yielding a defective 
coating, especially on the borders, as depicted in Figure 9A and 9B. For that reason, there 
was the need to optimize the spin coating procedure for this kind of coverslips, which implied 
the acquisition of a new chuck for the spin coater, specifically designed for spin coating of 
square and bigger substrates. Also, slight changes of the spin coating recipe were 
implemented in an attempt to perfectly coat the coverslips. Nevertheless, a series of 
unsuccessful attempts led us to decide using only the plastic coverslips throughout this 
project, which do not require the spin coating procedure. 
 
 
 
 
 
 
 
 
 
 
Figure 9 - Defective PDMS coating in the custom-made glass coverslip, (A) seen with the naked eye and (B) 
amplified with a 4x magnification. 
3.1.2 Microcontact printing 
 Microcontact printing is a technique that requires a high methodology precision to 
achieve it perfectly. Several variables can influence the results of this technique and the 
process needs to be carefully and thoroughly executed to achieve perfect patterns, fully 
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filled with protein. In Figure 10A it is represented the stamp which was produced from a 
master, with the micropatterns (lines) inscribed on the top surface. The surface needed to be 
filled with the protein solution. In Figure 10B it is shown the stamp with the fibronectin 
solution on its surface and after dried with nitrogen gas. The micropatterned surface of the 
stamp was then turned and placed against the custom-made coverslip, as represented in 
Figure 10C, while manual pressure applied. Due to the lack of a stamp big enough that could 
cover the entire coverslip with the specified dimensions, it was necessary to perform this 
technique 3 times in order to pattern the entire coverslip. The fibronectin protein patterns 
were printed on the coverslip and images were taken by the BD Pathway 855, in the Cy3 (red) 
channel and are represented in Figure 10D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 - Protein patterns production on the custom-made coverslip. (A) Micropatterns created on the stamp by 
master replication; (B) fibronectin solution on the stamp’s surface; (C) Custom-made plastic coverslip used as 
substrate for uCP; (D) result of the uCP on the custom-made plastic coverslip, with a 4x magnification.  
3.1.3 Platform attachment 
 Once the microcontact printing was performed on the coverslip, it was ready to be 
attached to the bottomless 96-well plate. All the regions of the bottom were carefully filled 
with glue and the development of the gluing process can be observed on Figure 11A and 11B. 
After the plate was entirely filled with glue, the coverslip side with printed protein patterns 
was carefully overlapped to the plate and released when it perfectly fitted the bottom of the 
plate. Some pressure was first applied on the edges of the coverslip, so that it could be fixed 
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to the plate without sliding. An uniform pressure was applied with the cylinder roll to glue 
the rest of the coverslip to the plate, making sure that there were no air bubbles trapped 
between them, as exemplified in Figure 11C, otherwise there would be a “leakage effect” 
when performing cell culture in the plate, and the liquid within each well would be 
exchanged between the neighboring wells. The final result of the gluing procedure of the 
coverslip to the plate is shown in Figure 11D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 - Attachment steps of the customized coverslip to the bottomless 96-well plate, resulting in the 
obtainment of a functional platform. (A) and (B) Development of the gluing process of the bottom of the bottomless 
96-well plate. (C) Attachment of the protein patterned coverslip to the 96-well plate by applying uniform pressure 
with the cylinder roll. (D) Final result of the constructed platform.  
3.2 Hypertrophy experiment 
3.2.1 Matrigel and fibronectin 
Two different types of substrate were used to induce hypertrophy in an experimental 
setting. Although the intention was to control cardiomyocyte shape and orientation using the 
protein patterns, initially, cardiomyocytes were cultured in Matrigel- and fibronectin-coated 
96-well plates, at 5000 cells/well to monitor their behavior on these different substrates. 
After a 7 days culture, cells were fixed and stained for α-actinin and DNA counterstained by 
DAPI. The results for the control (Cardiomyocyte medium + Maturation medium) and for the 
two main hypertrophic stimuli used, i.e. ISO and FCS are shown in Figure 12. 
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Figure 12 - Cardiomyocytes cultured on Matrigel monolayer (A1, B1 and C1) and in fibronectin monolayer (A2, 
B2 and C2) in (A) control, (B) ISO and (C) FCS treatments, at 5000 cells/well, and immunostained for α-actinin 
(green) and DAPI (blue) (magnification: 20x). 
 
 Figure 11 observation makes it clear that cardiomyocytes failed to develop on the 
fibronectin substrate, especially when compared to Matrigel, with the exception of the FCS 
treated cells. Only in the latter treatment cardiomyocytes seemed to have adhered and 
further developed on the fibronectin. The same outcome was seen for higher cell densities, 
where cardiomyocytes failed to develop on fibronectin in (control and ISO conditions), being 
the FCS treatment the exception. Given that almost no cardiomyocytes could be detected in 
fibronectin, image analysis could not be performed for the fibronectin experimental-set; thus 
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only the pictures of higher densities, 10000 and 20000 cells/well, in Matrigel are shown in 
Figures 13 and 14, (also for the PE treatment). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 - Cardiomyocytes cultured on Matrigel monolayer in (A) control, (B) ISO, (C) PE  and (D) FCS, at 10000 
cells/well, and immunostained for α-actinin (green) and DAPI (blue) (magnification: 20x). 
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Figure 14 - Cardiomyocytes cultured on Matrigel monolayer in (A) control, (B) ISO, (C) PE  and (D) FCS, at 20000 
cells/well, and immunostained for α-actinin (green) and DAPI (blue) (magnification: 20x). 
 It was noticeable CMs adapted well in the Matrigel substrate, as seen previously for 
lower cell density. It is also observable an increase of the CMs and cell-agglomeration in 
control conditions, when compared to the hypertrophic treatments (Figure 14) which may 
lead to misleading and contradictory conclusions, regarding the treatments. Cell 
agglomeration may lead into the conclusion that “control” leads to increase of the CMs area, 
although we have had solid proof that the single CMs within the clusters were increased. This 
issue will be addressed and below in the "Measurements" subsection.  
3.2.2 Fibronectin patterns 
When the attachment of patterned coverslip to the bottomless 96-well plate was 
complete, cell culture was performed on it. The cardiomyocytes adhere only to the protein 
patterns and their shape and orientation was controlled. After result observation of the 
cultured cardiomyocytes on fibronectin monolayer it was added a pre-step on this 
experiment, so the cells could adapt better to this type of substrate in this assay. The images 
were processed and amplified from the originals, using ImageJ, to better observe the CMs. 
Processed results are shown in the Figures 15 and 16 and the original images are shown in the 
Supplementary data. 
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Figure 15 - Cardiomyocytes cultured on fibronectin patterns (horizontal lines) in (A) control, (B)  ISO, (C) PE and 
(D) FCS, at 10000 cells/well, and immunostained for α-actinin (green) and DAPI (blue) (magnification: 20x). 
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Figure 16 - Cardiomyocytes cultured on fibronectin patterns (horizontal lines) in (A) control, (B)  ISO, (C) PE and 
(D) FCS, at 15000 cells/well, and immunostained for α-actinin (green) and DAPI (blue) (magnification: 20x) 
  
 Contrarily to the expected, i.e. more adhered and developed cardiomyocytes, so that 
analysis could be correctly performed and yield statistically significant differences, very few 
cardiomyocytes could be detected when cultured on the fibronectin patterned lines, for all 
the treatments and cell densities tested (Figures 15 and 16). 
3.3 Segmentation  
 To perform single cardiomyocyte analysis it was firstly necessary to segment each cell 
within each picture. This segmentation process was based on the cardiomyocyte's nuclei, 
given by the DAPI staining and tracked by the BD Pathway 855, using a nuclei propagation 
method for that purpose. DAPI has the ability to stain the nucleus of every cell 
(cardiomyocytes and non-cardiomyocytes) of each setting. With the nuclei propagation 
method, the nucleus of each cell is identified and expanded until meeting the boundaries 
imposed by the α-actinin staining. α-actinin expression identifies only the structures and 
limits of the cardiomyocytes present in each setting. Therefore, the segmentation was only 
performed to the existent cardiomyocytes of the acquired pictures, through these two 
different channels. It is taken into account that each cardiomyocyte can be mono or 
binucleated and the distance between each of the nuclei was measured to assess whether 
they belong to the same cell or not. When the segmentation mask can fully define the 
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contours of each cell, the measurements can be made to single cardiomyocytes. An example 
of the segmentation mask used in this work is shown in Figure 17. 
 
 
 
 
 
 
Figure 17 - Single cardiomyocyte's limits detected and given by the segmentation mask (magnification: 20x). (A) 
Cardiomyocytes detected by the α-actinin (green) channel and cardiomyocyte segmentation represented with white 
lines. (B) Segmentation mask defining the cardiomyocyte's contours represented with white lines. 
3.4 Measurements  
3.4.1 Cardiomyocyte area 
 The segmentation mask was used to determine the limits of each cardiomyocyte and 
their area was estimated from it. The area units are provided in pixels, allowing only relative 
comparisons between the different treatments at different cell densities, both in Matrigel 
monolayer and on fibronectin microcontact printing (µCP) patterns, as shown in Figure 18. 
 
 
 
 
 
 
Figure 18 - Cardiomyocyte's area (in pixels) of the different treatments on Matrigel (on the left) and in 
fibronectin µCP patterns (on the right), for different cell densities.  
  
 Regarding the Matrigel substrate (Figure 18) it is shown that the FCS treatment was 
increasing the cardiomyocyte's area reaching almost a two-fold increase for some of the cell 
densities used, when compared to the control. This area increase pattern could be observed 
for the 2000, 5000 and 10000 cells/well densities. Contrariwise, in the 1000 cells/well density 
a bigger area increase in control rather than in FCS treated was registered, although in the 
20000 cells/well density, there was not a significant area increase in FCS. The other 
hypertrophic treatments, ISO and PE, did not result in significant area increase and even 
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revealed to be smaller for 1000 cell/well density, as happened to the FCS treatment for the 
same density. Also, the cardiomyocyte's area showed to be smaller for PE in the 2000 
cell/well density. A similar outcome could be observed for the fibronectin µCP patterns, in 
which a significant increase could only be observed for the FCS treatment and only at the 
15000 cells/well density.  
3.4.2 Sarcomere intensity 
 With each cell perfectly delimited the cardiomyocyte's sarcomeres can be evaluated. 
This is performed by using an integrational procedure that measure and sums the color 
intensity of each pixel within each cardiomyocyte. In the end, it is made an average from the 
entire set of cardiomyocytes for each image and cell density. The result is displayed in Figure 
19. 
 
 
 
 
 
 
Figure 19 - Cardiomyocyte's sarcomere intensity (in pixels) of the different treatments on Matrigel monolayer 
(on the left) and in fibronectin µCP patterns (on the right), for different cell densities.  
It was shown that in Matrigel the sarcomere intensity was increasing in ISO, reaching 
more than a two-fold increase on the 10000 cell/well density, and in FCS, except for the 1000 
cells/well density. Thus, in the FCS treatment it is observed an overall sarcomere intensity 
increase, also with the exception for the 1000 cells/well density set. Regarding the 
fibronectin patterns, only FCS treatment, in the 15000 cells/well density, led to a relevant 
intensity increase.  
 
3.4.3 Cardiomyocyte ratio 
 This measure is performed through the calculation of the total nuclei number present 
and the number of nuclei that belong indeed to cardiomyocytes. For each image, it is used 
the DAPI channel acquisition to evaluate the total number of nuclei and the α-actinin channel 
acquisition to verify which nuclei are also an integrant part of cardiomyocytes. With the 
resulting values from this operation it is constructed a ratio between the cardiomyocyte's 
nuclei and the total number of nuclei, and represented as a percentage (Figure 20). 
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Figure 20 - Cardiomyocyte's ratio (in percentage) of the different treatments on Matrigel monolayer (on the left) 
and in fibronectin µCP patterns (on the right), for different cell densities.  
The results displayed in Figure 20 indicate that in Matrigel, PE treatment enhanced 
the cardiomyocyte proliferation to close to 40%, when compared to control for the 2000 
cells/well density. The same cannot be affirmed for the other cell-densities analyzed where 
instead it was even registered a decrease in CM ratio. A consistent trend that would enable 
drawing conclusions about the CM ratio was not obtained for any of the hypertrophic 
treatments. In the fibronectin pattern experiment it was also registered an increase on 
cardiomyocyte's ratio of 50% in PE, when compared to control, but only for the 15000 
cells/well density. Although not significant, the 10000 cells/well density showed also an 
increase in PE as compared to the control. These results point for a certain effect of PE 
treatment in CM ratio, however, further experiments will be necessary for full confirmation. 
3.4.4 Elongation 
 Elongation is a measure of the degree of stretching acquired by cardiomyocytes, after 
being cultured in the presence of different hypertrophic treatments, where the null value 
means that the cardiomyocyte is completely circular and the highest percentage (100%) 
means that it is fully elongated. The obtained results are represented in Figure 21. 
 
 
 
 
 
 
 
 
Figure 21 - Cardiomyocyte's elongation (in percentage) of the different treatments on Matrigel monolayer (on 
the left) and in fibronectin µCP patterns (on the right), for different cell densities.  
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Both Matrigel and fibronectin substrates produced a similar effect on CM elongation, 
although the latter registered a slight increase when results are compared. It was not 
determined any significant changes in elongation when results are compared between the 
treatments and control in both substrates, indicating that neither the substrates nor the 
hypertrophic treatments used are relevant in CM elongation  
3.5 ECM protein combination  
3.5.1 Optimal concentration 
 A total of twenty seven protein combinations, using fibronectin, laminin and collagen 
IV and varying their individual concentration from 10, 20 to 50 µg/ml, were performed. The 
solutions were used to coat 96-well plates and each one was tagged, as schematized below on 
Table V. 
 
Table V - Identification of the different protein concentrations for fibronectin (FN), laminin (LMN) and collagen 
IV (COL), used for each tagged combination. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 It is important to stress that this experiment did not imply the use of the hypertrophic 
stimuli, since the primary goal was to identify the optimal protein combination that would 
provide the essential stimuli for enhanced cardiomyocyte adaptation and development. 
Pictures were acquired by using the BD Pathway 855, after cell staining, and image analysis 
was executed. Area, sarcomere color intensity and cardiomyocyte ratio measurements were 
applied to evaluate the optimal ECM protein combination and are represented in Figures 22, 
23 and 24, respectively. 
 
 
 
 
 
 
 µg/ml 
 
µg/ml 
 
µg/ml 
Combination FN LMN COL Combination FN LMN COL Combination FN LMN COL 
1 20 10 10 11 50 10 20 21 10 10 50 
2 20 10 20 12 50 10 50 22 10 20 10 
3 20 10 50 13 50 20 10 23 10 20 20 
4 20 20 10 14 50 20 20 24 10 20 50 
5 20 20 20 15 50 20 50 25 10 50 10 
6 20 20 50 16 50 50 10 26 10 50 20 
7 20 50 10 17 50 50 20 27 10 50 50 
8 20 50 20 18 50 50 50 
    
9 20 50 50 19 10 10 10 
    
10 50 10 10 20 10 10 20 
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Figure 22 - Cardiomyocyte's area (in pixels) on the different ECM protein combinations (from 1 to 27) and in 
controls: FN-10, FN-20 and FN-50 (fibronectin at 10, 20 and 50 µg/ml, correspondingly); LMN-10, LMN-20 and LMN-50 
(laminin at  10, 20 and 50 µg/ml, correspondingly); COL-10, COL-20 and COL-50 (collagen IV at 10, 20 and 50 µg/ml, 
correspondingly).  
 
 
 
 
 
 
 
 
Figure 23 - Cardiomyocyte's sarcomere color intensity (in pixels) on the different ECM protein combinations 
(from 1 to 27) and in controls: FN-10, FN-20 and FN-50 (fibronectin at 10, 20 and 50 µg/ml, correspondingly); LMN-
10, LMN-20 and LMN-50 (laminin at 10, 20 and 50 µg/ml, correspondingly); COL-10, COL-20 and COL-50 (collagen IV at 
10, 20 and 50 µg/ml, correspondingly).  
 
 
 
 
 
 
 
 
Figure 24 - Percentage of cardiomyocytes present on the different ECM protein combinations (from 1 to 27) and 
in controls: FN-10, FN-20 and FN-50 (fibronectin at 10, 20 and 50 µg/ml, correspondingly); LMN-10, LMN-20 and LMN-
50 (laminin at  10, 20 and 50 µg/ml, correspondingly); COL-10, COL-20 and COL-50 (collagen IV at 10, 20 and 50 
µg/ml, correspondingly). 
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 Image analysis enabled us to identify the optimal protein combination to be used in 
microcontact printing within our experimental setting. The cardiomyocyte adaptation and 
development were extracted by the interception of the area, sarcomere color intensity and 
cardiomyocyte ratio measurements (Figure 22, 23 and 24, respectively). A bigger area, higher 
sarcomere color intensity and higher cardiomyocyte ratio is assumed to confer a better 
phenotype status to the cardiomyocytes and, regarding these parameters, it was concluded 
that the combination 4 (area: 2638 pixels; intensity: 971 pixels; ratio: 47%) produced overall 
the best result. 
3.5.2 Protein patterns 
 In parallel, microcontact printing was performed on the plastic coverslips with two of 
the twenty seven combinations, chosen before obtaining results from the previous subsection 
due to a lack of time available to accomplish this last experiment. It was selected the 
combination 5 (fibronectin 20 µg/ml, laminin 20 µg/ml and collagen IV 20 µg/ml) and 
combination 18 (fibronectin 50 µg/ml, laminin 50 µg/ml and collagen IV 50 µg/ml) for that 
purpose and cardiomyocytes were seeded at 10000 cells/well and cultured for 7 days with the 
hypertrophic inducing treatments, ISO, PE and FCS with the two controls (Cardiomyocyte 
medium and Maturation medium). At day 7, cardiomyocytes were stained for α-actinin and 
DAPI. The results are shown below in Figure 25. 
 
                 Combination 5 - 20µg/ml                               Combination 18 - 50µg/ml 
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Figure 25 - Cardiomyocytes cultured on protein combination patterns (vertical lines) at 20 µg/ml (A1, B1, C1, D1 
and E1) and at 50 µg/ml (A2, B2, C2, D2 and E2) in (A) Cardiomyocyte medium, (B) Maturation medium, (C) ISO, 
(D) PE and (E) FCS,  with a density of 10000 cells/well, and immunostained for α-actinin (green) and DAPI (blue) 
(magnification: 20x). 
 
Overall, the microphotographs on the two different combinations appear to indicate that 
there is a higher percentage and a better development of cardiomyocytes on combination 5 
(left panel in Figure 25). Image analysis was performed to better determine which of these 
two combinations promote more adherence and higher development of cardiomyocytes, 
represented in Figure 26. 
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Figure 26 - Area, sarcomere color intensity and cardiomyocyte ratio measurements of the cardiomyocytes on 
ECM protein patterns using combinations 5 (on the left) and 18 (on the right).  
No relevant differences could be spotted regarding cardiomyocyte's area, when 
comparing between the different treatments for both combinations. Sarcomere color 
intensity presented the lowest values in CM control for both combinations and the highest for 
FCS treatment in combination 18. Cardiomyocyte ratio evidenced the highest values in CM 
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control, in both combinations. In general, no significant alterations on cardiomyocyte's 
phenotype occurred when comparing the two different combinations, based on these 
measurements. 
Chapter 4 Discussion 
 
The two different acquired types of custom-made coverslips (glass and plastic) 
require the printing of protein patterns on their surface, through microcontact printing. As 
stated before, glass coverslips entail need to be spin coated with a PDMS solution for 
subsequent microcontact printing. This occurs due to the difficulty on enhancing the protein 
bonding by chemical activation of the glass material. On the other hand, plastic coverslips do 
not necessitate spin coating, and instead, microcontact printing can be performed directly, 
prior to the attaching to the bottom of a bottomless 96 well-plate. The final goal is to culture 
cardiomyocytes in these plates, induce CM hypertrophy and perform image analysis in order 
to obtain area and sarcomere intensity measurements. To this end, it was required that the 
coverslips met specific characteristics. First, they needed to be as flat as possible for an 
efficient spin coating and microcontact printing to be accomplished. Secondly, they needed 
to possess specific dimensions so they could perfectly fit into the bottom of the bottomless 96 
well-plate. Also, it was very important to control the thickness of the coverslips to guarantee 
optimal imaging resolution. If the coverslip is too thick, imaging would not be precise and 
cardiomyocyte’s structure would not be clearly displayed. Thirdly, it was crucial for them to 
be transparent to allow proper image acquisition.  
While testing the acquired glass coverslips it was found that they were not suitable 
for the kind of work required in the herein thesis plan. As stated before, these coverslips 
need to be spin coated with PDMS first, due to the nature of their composition, before 
printing the protein patterns onto it (Griffin, 1954; Blinka et al., 2010; Kaufmann and Ravoo, 
2010). However, after several attempts it was observed the same "string effect" pattern on 
the borders. This could be consequence of several factors which could not be exactly 
determined. It could be the effect caused by non-suitable spin coating program implemented 
for a coverslip with such big dimensions (i.e.111mmx75mm). The PDMS solution deposited 
upon the coverslip dries within the first minutes of the spin coating program (Théry and Piel, 
2009) and if the program is too fast or too slow the coating will not be perfect. An 
optimization of the recipe program could not be successfully determined to address this 
problem. It can also rely on the geometry of the substrate and there are three main issues 
regarding the spin coating of rectangular substrates: (1) the properties of fluid coating the 
substrate can produce edge beads which can also occur regardless of the substrate geometry 
(Carcano, Ceriani and Soglio, 1993; Atthi et al., 2009); (2) the geometrical effect of the 
substrate can create irregular coating patterns. This happens because of the increasing 
friction with the air at the periphery, which causes an increase of the evaporation rate of the 
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coating fluid and the formation of a dry skin at the corners of the substrate, restricting fluid 
flow. The fluid at the center of the substrate, which is still being driven out by centrifugal 
forces, flows over the dry film and dries, building up at the corners (Carcano, Ceriani and 
Soglio, 1993; Hui, Blosiu and Wiberg, 1998; Atthi et al., 2009); (3) the Bernoulli effects, which 
results of the leading edge of the substrate and because of the contact angle formed by the 
edge bead, creating an airfoil and causing the air streamline to separate while the substrate 
spins. Upon the formation of an edge bead on the top side, the air streamline is cut into 
unequal paths causing the air, which is flowing over the longest path (top side) to accelerate 
and the one which is flowing over the shortest path (bottom side) to decelerate. The 
acceleration on the top decreases pressure, enhancing the evaporation rate and causing a 
buildup in the corners (Carcano, Ceriani and Soglio, 1993; Atthi et al., 2009). A feasible 
solution to perfectly spin coat the rectangular custom-made glass coverslips could rely on the 
optimization of the spin coater machine. The chuck incorporated in the spin coater is, 
generally, used for smaller and round coverslips and it is not adapted for the type of 
coverslips used in this project, mainly due to aerodynamics constrains. It was advised by the 
supplier to acquire a specialized chuck for the purpose of the work herein, i.e. Embedded 
Vacuum chuck (Laurell Technologies). However, due to the lead time and financial costs 
required for this acquisition, different solutions were considered.  
For these reasons and due to the complications implied in the process a solution was 
found that involved a different approach. Thus, plastic coverslips were acquired with the 
same dimensions of the previous ordered glass coverslips, which do not require a spin coating 
process, and allowed for direct microcontact printing. Microcontact printing is a technique 
which requires a high methodology precision. First, the stamp needs to be completely dried in 
order for the technique to be succeeded, otherwise, the fibronectin, which is placed on the 
surface of the stamp will not spread over the entire surface (Théry and Piel, 2009). Secondly, 
the fibronectin solution needs to be in incubation on the stamp for long enough so it can 
infiltrate into the patterns designed on it (Théry and Piel, 2009). The first utilization of the 
day of the stamp requires more time than usual for the fibronectin penetrate into the 
patterns (1 hour). However, if the stamp is wet for long and for constant periods of time, it 
can be noticed that the fibronectin does not spread as easily on the next utilizations. It 
means that the incubation time cannot be for too short because the solution will not 
penetrate the entire stamp pattern, but it also cannot be for very long time or it will not be 
able to dry completely for the next utilizations. Thirdly, after the incubation period it is 
possible to print the protein pattern in the substrate and it will be transferred from the stamp 
to the substrate. For this to happen, the stamp needs to be placed in contact with the 
substrate and pressure needs to be applied on it. If enough pressure is not applied, the 
pattern that will be transferred to the substrate will be imperfect and defective because the 
protein will not be transferred in its totality. The regions where not enough pressure was 
applied will present lack of intensity or even a gap, which indicates no protein to almost 
none, was passed to the substrate. That can later influence cell's adhesion and phenotype to 
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the protein patterned on the substrate. On the other hand, if too much pressure is applied 
unwanted protein lines will be observed on the substrate. It happens when the stamp's sealing 
touches the substrate causing an extra unwanted line between the desired protein lines. This 
can, also, influence cell organization and can give rise to cardiomyocyte clusters because of 
the proximity of the lines. So it is always a compromise with the optimum amount of force to 
be applied to accomplish the best results. Once the protein patterns are printed on the 
coverslip, the process of its attachment to a bottomless 96-well plate can be initialized. 
Despite the optimizations regarding the platform construction it is still a low-throughput 
process, contrary to what was initially intended. The bottom of the plate needs to be entirely 
covered by glue to assure that the space between the coverslips and the plate is completely 
sealed. Since the attachment procedure is done manually, it accounts for a certain amount of 
time (aprox. 30 min) for each constructed plate, contradicting the principle of high-
throughput system. However, the implementation of a faster process for that purpose seems 
not to be a concern, since there are commercial solutions available. The commercial 
existence of a bottomless 96-well plate with a double sided tape, with one of the sides 
already attached to the plate would be a solution for the problem, where it would just be 
needed to attach the patterned coverslip.  
Initially, different substrates were used to test the hESC-derived cardiomyocyte 
behavior when cultured on them such as fibronectin and Matrigel. These experiments were 
conducted on fibronectin- and Matrigel-coated 96-well plates so the CM behavior could be 
compared between both substrates and for later estimation of CM adaptation and 
development on fibronectin patterned lines. It was undoubtedly shown that CM adaptation 
and development on fibronectin monolayer was very low, especially when compared to the 
CM status on the Matrigel formulation. This indicates that it would be more suitable to 
perform Matrigel protein patterns through microcontact printing, than the FN patterns, once 
it is evidenced that CM failed to develop on the FN substrate. However, the nature of the 
Matrigel formulation makes it very difficult to use for that purpose. Matrigel polymerizes very 
fast when at room temperature (RT) and microcontact printing requires a period of 
incubation of, at least, 30 min, at RT, hence decreasing the probabilities of successful 
printing. For this reason, Matrigel was not used to create protein patterns on the coverslips in 
this project, presenting, although, as a good alternative for other potential settings. Despite 
the inability to meet the expected results in the initial experiments, FN was tested for the 
creation of the protein patterns, in microcontact printing. However, the experimental setting 
suffered an alteration, aiming for a better adaption of the CMs. The time-course of the 
experiment was prolonged to a total of 14 days (7 days more than the usual duration of the 
previous experiments) in which CMs are cultured on FN coated-6-welll plates for the first 7 
days. This prolongation was carried on the attempt for the CMs to adapt better to this 
substrate before culturing them into the confined FN lines. Nevertheless, after the 14 days, 
very few CMs could be observed after cell staining, possibly indicating that FN by itself was 
not being capable to properly regulate CM adherence and/or development. Several attempts 
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to culture CMs in fibronectin substrate (either on monolayer or patterns) failed, which lead us 
to this conclusion. Thus, different fibronectin batches were used always with the same 
outcome. Studies suggest an important contribution of fibronectin in CM adhesion and 
differentiation (Horton et al., 2009; Wu et al., 2010), contradicting such conclusions. Reasons 
for the maladaptation of CMs to this substrate were undetermined.   
 Regarding the image analysis performed for the Matrigel experiment some trends 
could be revealed, although more repetitions are needed to substantiate conclusions. In fact, 
results were not totally consistent, but it could be observed that FCS treatment triggered 
higher hypertrophic responses when compared to the remaining treatments used in this work 
(ISO and PE), considerably increasing area and sarcomere intensity on CMs. That is not visible, 
from the mentioned measurements, for all of the tested cell densities which is a source of 
uncertainty in regard to the collected experimental data, given that the added stimulus is 
well known as inducing a hypertrophic effect on CMs (Dubey et al., 1997; Schäfer et al., 
2002). Plus, the same can be said about the other used hypertrophic stimuli, ISO and PE, 
(Taigen et al., 2000; Zou et al., 2001) which did not show in this work to have the effects 
reported on the CMs. Further experiments would be necessary to clarify these results and to 
obtain more consistent conclusions. A hypothesis for the lack and/or inconsistent 
hypertrophic response on the CMs could be the administration of low concentrations of the 
hypertrophic inducers used. Although, support is found in the literature for the used 
concentrations, the reports in the area seem contradictory. For example, Putinsky and 
colleagues (2013) use 100µM of PE, instead of the 10µM used in this project. On the other 
hand, Földes and colleagues (2011) used the same concentration of PE as in the present study 
(10µM) and registered an area increase, sarcomere rearrangement and others markers that 
pointed to CM hypertrophy. However, the hESC-derived CMs used in the later work were in a 
more mature state which may or may not influence hypertrophy. Also, the period of 
treatment administration was shorter. Treatment concentration and duration and/or CM 
maturation level can be influencing the results, although we have not got so far the evidence 
to support such assumption.  
 The area and sarcomere color intensity analysis performed on the CMs cultured on the 
FN µCP patterns appears to indicate that the FCS treatment produces higher hypertrophic 
effects, presenting a bigger area and higher sarcomere intensity when compared to the other 
stimuli. However, the results do not show consistency, since this is not observed for all the 
cell densities. This may also derive from the difficulty in the CMs adaptation and development 
on the confined patterns on the well. The CM ratio performed both to Matrigel and FN 
patterns did not provide additional useful information to better describe the hypertrophy 
state of the CMs, since the results were not conclusive. Nevertheless, the CM culture 
conditions at higher densities, 10 and 20 cells/well, seems to enhance CM proliferation, as 
shown by the general higher CM percentage at these cell-densities. There is also the 
possibility that the PE treatment enhances proliferation, just confirmed by the high 
percentages on the 2000 cells/well density in Matrigel and in 15000 cells/well density in the 
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FN patterns. Although it is important to stress that the CM ratio is relative to the total 
number of cells present, i.e. cardiomyocytes and non-cardiomyocytes, being not truly reliable 
when assessing the cardiomyocyte's adaptation, development and/or proliferation on the 
different substrates and treatments. Contrariwise, area, sarcomere intensity and elongation 
are absolute measurements, in which just the CMs are evaluated, and can better describe CM 
behavior in the different treatments. The elongation study proved that the treatments do not 
significantly alter the elongation profile of CMs. 
The results obtained from the FN patterns are not very elucidative because very few 
CMs could be observed in the images, thereby indicating they did not adapt well to the µCP 
lines. A different approach was needed for the optimal adherence of the CMs to the protein 
patterns for accurate analysis to be conducted. Considering the high CM population seen on 
the Matrigel substrate, that option was explored to produce the protein patterns. The 
Matrigel's composition was investigated to determine which compound(s) where decisive in 
CM adaptation and development. It was found that it is mainly composed by laminin (60%), 
collagen IV (30%) and entactin (8%) (Kosovsky, 2009). Knowing the importance of these 
compounds and also of fibronectin in native CM development (Horton et al. 2009) it was 
rehearsed a combination of laminin, fibronectin and collagen IV. It was experimented every 
possible combination from using the three proteins together to varying their individual 
concentration between 10, 20 and 50 µg/ml, making a total of twenty seven different 
combinations (3 different concentrations that can be assigned for each of the 3 proteins), to 
determine which one would provide the best results. Microphotographs were obtained for 
each combination and for the controls (they were all seeded in duplicate) which were then 
further analyzed. Cardiomyocyte's area, sarcomere color intensity and ratio parameter were 
analyzed for aiding on determining the best protein combination to be used. High values for 
these three measurements would mean a greater CM adaptation and development to the 
substrate. The best protein combination was determined based on the overall best score of 
the interception of the three measurements. Owing to the lack of time available to identify 
the optimal individual protein concentration to be used in a combined solution, two of the 
twenty seven combinations were chosen before full data analysis. In parallel it was performed 
microcontact printing with these two combinations: 20 and 50 ug/ml for each and all of the 
three proteins, reaching a solution final concentration of 20 and 50 ug/ml (combination 5 and 
18). These concentrations were chosen since they were used throughout the project for 
coating and patterning processes, respectively.    
Later, it was concluded that the combination number 4 was the one that had the best 
relative higher results in the three measurements. This combination is composed by 
fibronectin at 20 µg/ml, laminin at 20 µg/ml and collagen IV at 10 µg/ml and by this analysis 
it would be the selected formulation to use for microcontact printing, since it would be the 
one capable of providing the stimuli for a better cardiomyocyte's growth, development and 
adaptation, under our culture conditions. These conditions are fundamental to obtain proper 
and reliable information about the hypertrophy phenotype. However and as stated before, 
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due to the delay on obtaining knowledge of the optimal concentration to use, combination 5 
and 18 were used for microcontact printing instead. Both protein combination patterns 
showed to produce a better effect than the fibronectin patterns. It is visible the existence of 
more CMs that adhered and developed on these combinations, when compared to the 
fibronectin patterns with the same cell density, suggesting that future work should involve 
more testing with similar protein combination. 
The evaluation of the measurements destined to establish the optimal concentration, 
performed by monolayer coating (subsection 3.5.1) indicated a better CM overall status in 
combination 5 rather than combination 18. However, the measurements performed to the 
CMs cultured in the patterned protein combinations 5 and 18 (section 3.5.2), showed no 
relevant differences to report. Thus, hypertrophic treatments seem, once again not be 
producing the expected effects on CMs, or at least, their effect seem not to be conclusive, 
which can mean that either the used CMs do not respond to these stimuli for the reasons 
previously addressed, the procedure is not correctly performed and/or image analysis and 
measurements need to be optimized. 
 
Chapter 5 Conclusions  
 
 The aim of this study was to create in vitro a system to model cardiac disease, namely 
that relating to CM hypertrophy, in which multiple samples could be screened in high-
throughput fashion. Such system would have to be robust and enable thorough evaluation the 
hypertrophy phenotype. Based on this study the following conclusions can be taken: 
 The platform used to study the hypertrophy was successfully constructed and 
optimized for high-throughput studies, offering the ability to culture a high number of 
cells on a vast area filled with protein patterns. 
 Fibronectin substrate on its own, does not seem to be suitable for this assay. 
 Matrigel’s components support better CM adherence, development and proliferation 
when compared to fibronectin.  
 Cardiomyocyte's area seems to be slightly increased with the FCS treatment, although 
further experimentation is needed to consistently affirm that. 
 CM maturation level, concentration and duration of hypertrophic treatments, 
experimental errors and/or lack of optimization of image analysis for this work can be 
influencing the results. 
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Chapter 6 Future Perspectives 
 
 Nowadays, the study of the heart has been increasing through the improvement of the 
signalling cascade needed to provide, in order to successfully differentiate the pluripotent 
stem cells into cardiomyocytes (Beqqali et al., 2009). However, many questions remain 
unanswered relating to the phenotype and genotype of the cardiomyocytes obtained by this 
process, which may not completely resemble the native ones. For a better understanding of 
the phenomena associated with cardiomyocyte hypertrophy, which can lead to heart failure, 
it is imperative to develop new tools that can be used to study this event in better detail. 
With the knowledge acquired from this study will come beneficial progresses that allow a 
more efficient methodology to address this problem. The created platform to study this 
disease was constructed with those purposes, although several optimizations are still required 
to increase the throughput of platform construction and sample screening, and also improve 
result precision. 
 The platform construction implies a long manufacture gluing procedure, affecting the 
analysis efficiency. The bottom of the 96-well plate needs to be fully glued, to avoid fluid 
leakage when the coverslip is attached and cell culture is performed on the platform. Even 
though a double-sided tape was implemented in an attempt to optimize this process, its 
efficiency did not increase. This time consuming procedure could be avoided by the 
acquisition of an existent commercial product. A 96-well plate with an integrated adhesive 
tape on its bottom (ProPlate MPTM microtiter plate superstructure GBL204969, Grace Bio-Labs) 
is presently available in the market and could be easily used to attach the patterned 
coverslip, increasing process' efficiency and the throughput level. A robotic arm incorporated 
to the BD Pathway 855 could also be used to automatically insert in the system and screen 
multiple cell culture plates, enhancing efficiency.   
 An inherent problem regarding the plastic coverslips derives from the flexible 
properties of it. Their ability to easily bend when force is applied can produce topographic 
irregularities when attaching it to the bottomless 96-well plate. This would create different 
undulations in each well and, therefore, origin different cell depth, which would alter camera 
focus for each well. Although many of the present bioimaging systems have an automatic 
focus feature, it was working deficiently for the system used in this project, the BD Pathway 
855, compromising the image focus randomly. Both of the shortcomings, topography 
irregularity and deficient focus, would need to be corrected and optimized for a proper 
hypertrophy analysis of cardiomyocytes. The re-incorporation of the glass coverslips in the 
platform and the repair and optimization of the autofocus system would be fundamental for 
improving results precision. 
 After applying the mentioned functional optimizations, other hypothesis and theories 
would be tested in the attempt to obtain numerous and "healthy" cardiomyocytes to be 
analysed, such as the use of the proper protein combination for microcontact printing. 
Regarding the results on section 3.5.1 the optimal protein combination that would allow a 
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better cardiomyocyte development and adaptation would be combination 4 (fibronectin at 20 
µg/ml, laminin at 20 µg/ml and collagen IV at 10 µg/ml) and this would be the one used in 
the future, since the lack of time available dictated that it would not be performed. 
Concerning the apparent lack of hypertrophic effect on the cardiomyocytes after 
hypertrophic treatments administration, it would be interesting to use a DNA microarray to 
measure the gene expression level of multiple regions of the genome, with special interest in 
the immediate early genes (c-jun, c-fos, c-myc) and the fetal genes (ANF, β-MHC and SKA) 
(Friddle et al., 2000; Du, 2007; Rohini et al., 2010). This genes are known to be activated 
during the development of cardiomyocyte hypertrophy condition and it would be possible to 
determine if the hypertrophic treatments used in this project were triggering or not those 
effects, since the data analysis could not totally conclude about that. The proper decisions 
would be adopted regarding the DNA microarray results.  
  As soon as the platform is properly working and optimized it can be used as a human 
disease in vitro model for pre-clinical studies. The certification of a drug is known to be a 
very slow and expensive procedure and it may take the minimum duration of 15 years, being 
divided into 3 phases: drug discovery, drug development and clinical trials. The last stage, 
only, can cost up to 120 million American dollars (DiMasi, Hansen and Grabowski, 2003). For 
this fact, the created model can be used to test drugs and if they indirectly affect the heart, 
it would be shown by the morphological analysis. Since almost all therapeutic drugs used to 
cure certain organs, such as the liver and kidney, produce an adverse effect on the heart, it 
would be extremely useful and beneficial the use of such a platform in pre-clinical studies, to 
obtain an immediate response of the heart cells to such compound. This would also prevent 
drug owners to disburse the enormous quantity of money needed to proceed to clinical trials, 
if cardiomyocyte's response to the drug is not appropriate (e.g. induction of hypertrophy)  
(DiMasi, Hansen and Grabowski, 2003; Braam, Passier and Mummery, 2009). 
Another application of the created tool relies in the possibility of testing cardiac 
toxicity when a specific compound is introduced on the hESC-cardiomyocyte environment. 
The measure of key parameters, such as the effect of the test substance on the viability of 
the ESCs, can be used to predict the response of native cardiomyocytes to specific drugs 
(Rolletschek, Blyszczuk and Wobus, 2004). Plus, the model can be applied to many other 
projects where cardiomyocyte's morphologic characteristics need to be followed and studied. 
 Finally, but not the least, this work can provide interesting information about the ECM 
proteins and optimal protein concentration for an enhanced cardiomyocyte development.  
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Figure 27 - Original images of cardiomyocytes cultured on fibronectin patterns (horizontal lines) in (A) control, 
(B)  ISO, (C) PE and (D) FCS, at 10000 cells/well, and immunostained for α-actinin (green) and DAPI (blue) 
(magnification: 20x). 
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Figure 28 - Original images of cardiomyocytes cultured on fibronectin patterns (horizontal lines) in (A) control, 
(B)  ISO, (C) PE and (D) FCS, at 15000 cells/well, and immunostained for α-actinin (green) and DAPI (blue) 
(magnification: 20x). 
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